VASO Corp 10-K for FY2024
VASO Corp (VASO)
About this 10-K
VASO Corp filed this 10-K on March 31, 2025, covering the fiscal year ended December 31, 2024 (FY2024).
Headline figures
Fiscal year ended December 31, 2024, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $86.77M
- up 7.1% from $81.02M a year earlier
- Net income
- $951K
- down 80.2% from net income of $4.81M a year earlier
- Diluted EPS
- $0.01
- down 66.7% from $0.03 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
For the fiscal year ended
Commission File No.
(Exact name of registrant as specified in Its Charter)
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone
number, including area code:
Securities registered under Section 12(b) of the Act: None
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Securities registered under Section 12(g) of the Act:
Common Stock, $.001 par value
(Title of Class)
Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act. Yes ☐
Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Indicate by check mark whether the
registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to
submit such files)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ | Smaller reporting company | |
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on
and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
If securities are registered pursuant to Section 12(b) of the Act,
indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to
previously issued financial statements.
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
The aggregate market value of
common stock held by non-affiliates was approximately $
At March 24, 2025, the number
of shares outstanding of the issuer’s common stock was
DOCUMENTS INCORPORATED BY REFERENCE
{THIS PAGE LEFT INTENTIONALLY BLANK}
VASO CORPORATION
INDEX TO FORM 10-K
EXHIBITS
| Exhibit 31 | Certifications Pursuant to Securities Exchange Act Rule 13A-14(A)/15D-14(A) |
| Exhibit 32 | Certifications Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
i
PART I
ITEM 1 – BUSINESS
The information contained in this report contains forward-looking statements (as such term is defined in the Securities Exchange Act of 1934 and the regulations thereunder). These forward-looking statements may include projections of, or guidance on, the Company’s future financial performance, expected levels of future revenue and expenses, anticipated growth strategies, and anticipated trends in the Company’s business or financial results. When used in this report, words such as “anticipates”, “continue”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential”, “future”, “intends”, the negative of these terms and similar expressions identify forward-looking statements. Any forward-looking statement made by the Company in this document is based only on the Company’s current expectations, estimates and projections about future events and financial trends affecting the financial condition of its business based on information currently available to the Company and speaks only as of the date when made. Forward-looking statements are not historical facts or guarantees of future performance. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control, and actual results may differ materially from this forward-looking information and therefore, should not be unduly relied upon. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn or disruptions in the U.S. economy; the impact of US tariff policies; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries.
General Overview
Vaso Corporation (the “Company”) principally operates in three distinct business segments in the healthcare equipment and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments.
| ● | IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc. (“VasoTechnology”), primarily focuses on healthcare IT and managed network technology services; |
| ● | Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GE HealthCare Technologies, Inc. (“GEHC”) into the health provider middle market; and |
| ● | Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively. |
The Company’s website is www.vasocorporation.com.
VasoTechnology
VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”). VasoTechnology currently consists of a managed network and security service division (NetWolves) and a healthcare IT application VAR (value added reseller) division (VasoHealthcare IT). Its current offerings include:
| ● | Managed healthcare software solutions including diagnostic imaging applications (channel partner of select vendors of healthcare IT products). | |
| ● | Managed network infrastructure (routers, switches and other core equipment). | |
| ● | Managed network transport (FCC licensed carrier reselling 175+ facility partners). | |
| ● | Managed network security services. |
VasoTechnology uses a combination of proprietary technology, methodology and best-in-class third-party applications to deliver its value proposition.
1
VasoHealthcare
VasoHealthcare commenced operations in 2010, in conjunction with the Company’s execution of its exclusive sales representation agreement with GEHC to further the sale of certain medical capital equipment in certain domestic market segments. Its current offerings consist of:
| ● | GEHC diagnostic imaging equipment and ultrasound systems. | |
| ● | GEHC service agreements for the above equipment. | |
| ● | GEHC training services for use of the above equipment. | |
| ● | GEHC and third-party financial services for the above equipment. |
VasoHealthcare has built a team of over 80 highly experienced sales professionals who utilize proprietary sales management and analytic tools to manage the complete sales process and to increase market penetration.
VasoMedical
The proprietary medical equipment business under VasoMedical dates back to 1995 when the Company began the proprietary Enhanced External Counterpulsation (EECP®) technology in the United States, and has since diversified to include other medical hardware and software. Vasomedical Global was formed in 2011 to combine and coordinate the various international operations including design, development, manufacturing, and sales of medical devices and software, while domestic activities are conducted under Vasomedical Solutions. VasoMedical’s proprietary devices and software primarily consist of cardiovascular diagnostic and therapeutic applications, including:
| ● | Biox® series Holter monitors and ambulatory blood pressure recorders. |
| ● | ARCS® series analysis, reporting and communication software for ECG and blood pressure signals, including cloud-based software suite and algorithm in the form of a SaaS (software as a service) subscription. |
| ● | MobiCare® multi-parameter wireless vital-sign monitoring system. |
| ● | EECP® therapy systems for non-invasive, outpatient treatment of ischemic heart disease. |
This segment uses its extensive in-house knowledge and intellectual property for cardiovascular devices and software coupled with its engineering resources to cost-effectively create and market its proprietary technology. It sells and services its products to customers in the U.S. and China directly and sells and/or services its products in the international market mainly through independent distributors.
Historical Background
Vaso Corporation was incorporated in Delaware in July 1987. For most of its history, the Company primarily was a single-product company designing, manufacturing, marketing and servicing its proprietary Enhanced External Counterpulsation, or EECP®, therapy systems, mainly for the treatment of angina. In 2010, it began to diversify its business operations. The Company changed its name to Vaso Corporation in 2016 to more accurately reflect the diversified nature of its business and continues to use the original name VasoMedical for its proprietary medical device subsidiary.
In May 2010, the Company launched its Professional Sales Service business through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, which was appointed by GEHC as its exclusive representative for the sale of select GEHC diagnostic imaging equipment, and expanded in 2023 to include ultrasound systems, to specific market segments in the 48 contiguous states of the United States and the District of Columbia. The original agreement with GEHC (“GEHC Agreement”) was for three years ending June 30, 2013; it has been extended several times with the current extension through December 31, 2026, subject to earlier termination under certain conditions.
In June 2014, the Company began its IT segment business by entering into a Value Added Reseller Agreement (“VAR Agreement”) with GEHC to become a national value added reseller of then GEHC Digital’s software solutions such as Picture Archiving and Communication System (“PACS”), Radiology Information System (“RIS”), and related services, including implementation, training, management and support. This business focuses primarily on customer segments currently served by VasoHealthcare. A new wholly owned subsidiary, VasoHealthcare IT Corp. (“VHC IT”), was formed to conduct the Company’s healthcare IT business. In 2021, the VAR Agreement was terminated and the Company partnered with other vendors providing similar products.
2
In May 2015, the Company further expanded its IT business segment by acquiring all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”), pursuant to an asset purchase agreement. NetWolves designs and delivers efficient and cost-effective multi-network and multi-technology solutions as a managed network provider, as well as provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution.
The Company’s proprietary equipment business also has been significantly expanded from the original EECP®-only operations. In September 2011, the Company acquired FGE, a British Virgin Islands company, which owned or controlled two Chinese operating companies - Life Enhancement Technology Ltd. (“LET”) and Biox Instruments Co. Ltd. (“Biox”) - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Biox was a variable interest entity (“VIE”) controlled by FGE through certain contracts and an option to acquire all the shares of Biox by FGE’s wholly owned subsidiary Gentone, and in March 2019 Gentone exercised its option to acquire all of the shares of Biox. In August 2014, the Company through Gentone acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (“Genwell”), which was formed in 2010 to develop the MobiCare® wireless multi-parameter patient monitoring system and holds intellectual property rights for this system. As a result, the Company has expanded its equipment products portfolio to include Biox® series ambulatory patient monitoring systems, ARCS® series cloud-based software suite and algorithm for ECG and blood pressure monitoring and analysis, and the MobiCare® patient monitoring device.
In April 2014, the Company entered into a cooperation agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (“PSK”) of Chongqing, China, the leading manufacturer of external counter pulsation, or ECP, therapy systems in China, to form a joint venture company, VSK Medical Limited (“VSK”), a Cayman Islands company, for the global marketing, sale and advancement of ECP therapy technology. The Company owned 49.9% of VSK, which commenced operations in January 2015. In March 2018, the Company terminated the cooperation agreement with PSK and sold its shares in VSK to PSK. On May 20, 2020, the Company closed on the sale of 51% of the capital stock of its wholly-owned subsidiary EECP Global Corporation (“EECP Global”) to PSK. EECP Global was formed in September 2019 to hold all the assets and liabilities of its EECP business. Concurrently with the closing of the transaction, the Company signed Management Service Agreement with EECP Global to provide management service for the business and operation of EECP Global in the United States. The agreement provides an initial term of three years starting April 1, 2020, the effective date of the sale, which is automatically renewable for additional one-year terms. The agreement’s current term ends April 1, 2025 and will be automatically renewed for another year. Pursuant to the agreement, EECP Global reimburses the Company all direct expenses and pays a monthly management fee during the term of the agreement.
Termination of Achari Business Combination Agreement
As previously disclosed, the Company entered into a business combination agreement (the “Business Combination Agreement”), dated as of December 6, 2023, with Achari Ventures Holdings Corp. I, a Delaware corporation (“Achari”), and Achari Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Achari (“Merger Sub”). The Business Combination Agreement provided, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub would merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Achari. On September 17, 2024, Vaso provided to Achari a notice of termination of the Business Combination Agreement. Business combination transaction costs presented in the Consolidated Statements of Operations and Comprehensive Income (Loss) include investment banking and other advisory and legal costs incurred in connection with the Business Combination Agreement, as well as the write-off of $508,000 in transaction costs capitalized in prior quarters of 2024.
Management
The Company currently bases its headquarters in Plainview, Long Island, NY pursuant to a lease which expires in September 2028. The Company’s executive officers include its President and Chief Executive Officer (“CEO”), Chief Operating Officer (“COO”), and Chief Financial Officer (“CFO”).
The management of the Company’s IT segment is led by the President of VasoTechnology and NetWolves, which is based in Tampa, FL. Our VasoHealthcare IT business is organized as a part of VasoTechnology and is based in Nashville, TN. VasoHealthcare IT works with our VasoHealthcare diagnostic imaging equipment sales team to generate leads and potential clients for the software solutions products and works with NetWolves sales and technical teams for comprehensive IT product and service offerings.
3
In the professional sales services segment, we sell GEHC diagnostic imaging products and ultrasound systems to our assigned accounts in the 48 contiguous states of the United States and the District of Columbia through a nationwide team of approximately 70 sales employees led by several regional managers and an executive team who report to the President of VasoHealthcare. The operation is also supported by in-house administrative, analytic, technical and other support staff, as well as applicable GEHC employees.
The equipment segment is under the direct supervision of the CEO of the Company. Regulatory, technical, sales and marketing efforts in the domestic market are led by a Vice President Operations at VasoMedical, and the managers of our China subsidiaries, based in Wuxi, China, are in charge of the development and production of all our proprietary products and marketing and sales in China and the international markets. We sell our Biox® series and other products in China through a group of sales managers as well as through distributors covering various regions of China and other international geographies.
Competition
In the U.S. diagnostic imaging market where we sell GEHC products, our main competitors are other diagnostic imaging equipment manufacturers such as Siemens, Philips, Canon, and Hologic, etc. as well as their channel partners and distributors. Key competitive factors in the market include price, quality, finance availability, delivery speed, service and support, innovation, distribution network, breadth of product and service offerings and brand name recognition. GEHC is a leading competitor in this market.
In the IT segment, our primary competitors in the healthcare IT VAR business are software solution providers such as Agfa Healthcare, McKesson, Philips, Carestream Health, etc. Key competitive factors are brand recognition, quality, radiology workflow solutions, scalability and service and support capability. In the managed network services business our primary competition includes, but is not limited to, organizations who have a presence in most of the major markets for the following products and services: network services, managed services, security services and healthcare applications. Several of those competitors, many of which are our vendors, are: Verizon, AT&T, CenturyLink, IBM and Cisco Resellers, Siemens, Epic, small regional IT integrators and large company internal IT departments.
In the ambulatory monitoring system business, there are numerous competitors of various size and strength. The Biox® product line is among the few from China with CE Mark certification for Europe, CFDA approval for China, US FDA clearances as well as Brazilian Agencia Nacional de Vigilancia Sanitaria (ANVISA) approval, which are among the most important qualifications to market and sell the products around the world.
Regulations on Medical Devices
As a medical device manufacturer and marketer, we are subject to extensive regulation by numerous government regulatory agencies, including the US FDA and similar foreign agencies. We are required to comply with applicable laws, regulations and standards governing the development, preclinical and clinical testing, manufacturing, quality testing, labeling, promotion, import, export, and distribution of our medical devices.
Compliance with Regulations in the United States
The Company has received appropriate US FDA premarket notification (510(k)) clearance for all its products marketed and sold in the United States, including EECP® therapy systems and Biox® ambulatory monitoring systems including ARCS® analysis and report software. We seek US FDA clearance or approval for new products prior to their introduction to the US market.
We are subject to other US FDA regulations that apply prior to and after a product is commercially released. We also are subject to periodic and random inspections by the US FDA for compliance with the current Good Manufacturing Practice, or cGMP, requirements and Quality System Regulation. The US FDA also enforces post-marketing controls that include the requirement to submit medical device reports to the agency when a manufacturer becomes aware of information suggesting that any adverse events are related to its marketed products. The FDA relies on medical device reports to identify product problems and utilizes these reports to determine, among other things, whether it should exercise its enforcement powers. The FDA also may require post-market surveillance studies for specified devices.
4
We are subject to the Federal Food, Drug, and Cosmetic Act’s, or FDCA’s, general controls, including establishment registration, device listing and labeling requirements.
The sales and advertising of our products is subject to regulation by the Federal Trade Commission, or FTC. The FTC Act prohibits unfair or deceptive acts or practices in or affecting commerce. Violations of the FTC Act, such as failure to have substantiation for product claims, would subject us to a variety of enforcement actions, including compulsory process, cease and desist orders and injunctions, which can require, among other things, limits on advertising, corrective advertising, consumer redress and restitution, as well as substantial fines or other penalties.
As a medical device sales channel partner and product reseller to healthcare facilities, we are subject to various federal, state and local laws targeting fraud and abuse in the healthcare industry, including anti-kickback and false claims laws.
Foreign Regulation
In most countries where we seek to export our medical devices, a local regulatory clearance must be obtained. The regulatory review process varies from country to country and can be complex, costly, uncertain and time-consuming. Our medical devices are all manufactured in accordance with ISO 13485 (Medical device – Quality management systems – Requirement for regulatory purpose), an internationally agreed standard that sets out the requirements for a quality management system specific to the medical devices industry. All our current medical devices have obtained necessary clearances or approvals prior to their release in the appropriate jurisdictions, including CE marking certification for European Union countries, China FDA (CFDA) approval for mainland China, Korean FDA (KFDA) approval for South Korea, Agência Nacional de Vigilância Sanitária (ANVISA) approval for Brazil, Taiwan FDA (TFDA) for Taiwan, and the Saudi SFDA (MDMA) for the Kingdom of Saudi Arabia.
We are also subject to audits by organizations authorized by foreign countries to determine compliance with laws, regulations and standards that apply to the commercialization of our products in those markets. Examples include auditing by a European Union Notified Body organization (authorized by a member state’s Competent Authority) to determine conformity with the Medical Device Directives (MDD) and by an organization authorized by the Brazilian government to determine conformity with the ANVISA requirement.
Patient Privacy
Federal and state laws protect the confidentiality of certain patient health information, including patient records, and restrict the use and disclosure of that protected information. The U.S. Department of Health and Human Services (HHS) published patient privacy rules under the Health Insurance Portability and Accountability Act of 1996 (HIPAA privacy rule) and the regulation was finalized in October 2002. Currently, the HIPAA privacy rule affects us only indirectly in that patient data that we access, collect and analyze may include protected health information. Additionally, we have signed some Business Associate Agreements with Covered Entities that contractually bind us to protect private health information, consistent with the HIPAA privacy rules requirements. We do not expect the costs and impact of the HIPAA privacy rule to be material to our business.
Regulations in the IT Business
As a reseller of telecommunication services and network solutions provider, our products and services are subject to federal, state and local regulations. These regulations govern, in part, our rates and the way we conduct our business, including the requirement to offer telecommunications services pursuant to nondiscriminatory rates, terms, and conditions, the obligation to safeguard the confidentiality of customer proprietary network information, as well as the obligation to maintain specialized records and file reports with the Federal Communications Commission and state regulatory authorities. While we believe we are in compliance with laws and regulations in jurisdictions where we do business, we continue to monitor and assess our compliance.
5
The Federal Communications Commission (“FCC”) exercises jurisdiction over services and regulates interstate and international communications in all 50 states, the District of Columbia and U.S territories. As an independent U.S. government agency overseen by Congress, the FCC is the United States’ primary authority for communications laws, regulation and technological innovation.
We maintain Certificates of Public Convenience and Necessity in all 50 states, which enable us to provide services within each state. We are therefore subject to regulation from the Public Utility Commissions in each state.
Intellectual Property
In addition to other methods of protecting our proprietary technology, know-how and show-how as well as trade secrets, we pursue a policy of seeking patent protection, both in the US and abroad, for our proprietary technologies including those in Biox® and MobiCare® products. Moreover, trademarks have been registered for the names “Vaso”, “Vasomedical”, “VasoGlobal”, “VasoSolutions”, “VasoHealthcare”, “EECP”, “Biox”, “ARCS” and “MobiCare”.
Through our China-based subsidiaries, we own thirty-five invention and utility patents in China that expire at various times through 2041, as well as twenty-two software copyright certificates in China related to proprietary technologies in physiological data acquisition, analysis and reporting. We also maintain five registered trademarks in China for our products.
Through our NetWolves subsidiary we hold the trademarks “NetWolves”, “SRM”, and “Wolfpac”.
There can be no assurance that our patents will not be violated or that any issued patents will provide protection that has commercial significance. As with any patented technology, litigation could be necessary to protect our patent position. Such litigation can be costly and time-consuming, and there can be no assurance that we will be successful.
Employees
As of December 31, 2024, we employed 298 full-time persons, of which 14 are employed through our headquarters and VasoMedical facility in Plainview, New York; 102 through VasoHealthcare; 16 through VasoHealthcare IT; 102 through our NetWolves operations; and 64 in our China operations. None of our employees are represented by a labor union. We believe that our employee relations are good.
The Company also retains several part-time employees and consultants from time to time for various purposes.
Manufacturing
The Company conducts manufacturing activities for its ambulatory monitoring devices and other medical devices in its Biox facilities in China, and maintains certain manufacturing capability in the Plainview, NY location to satisfy certain domestic and international needs for the EECP® systems per the management agreement with EECP Global.
All manufacturing operations are conducted under the cGMP requirements, as set forth in the FDA Quality System Regulation, as well as ISO 13485 (Medical device – Quality management systems – Requirement for regulatory purpose), an internationally agreed standard that sets out the requirements for a quality management system specific to the medical devices industry. We are also certified to conform to full quality assurance system requirements of the EU Medical Device Directive (MDD 93/42/EEC Annex II) and can apply CE marking to all of our current Biox product models. Lastly, we are certified to comply with the requirements of the Brazilian Agência Nacional de Vigilância Sanitária (ANVISA). All these regulations and standards subject us to inspections to verify compliance and require us to maintain documentation and controls for the manufacturing and quality activities.
We believe our manufacturing capacity and warehouse facility are adequate to meet the current and immediately foreseeable future demand for the production of our medical devices. We believe our suppliers of the other medical devices we distribute or represent are capable of meeting our demand for the foreseeable future.
6
ITEM 1A - RISK FACTORS
An investment in our securities involves certain risks, including, among others, the risks described below. You should carefully consider the risks and uncertainties described below, together with the information included elsewhere in this Report on Form 10K. The risks and uncertainties described below are those we have identified as material but are not the only risks and uncertainties facing us. Our business is also subject to general risks and uncertainties that affect many other companies, such as market conditions, geopolitical events, changes in laws or accounting rules, fluctuation in interest rates, terrorism, wars or conflicts, major health concerns, natural disasters or other disruptions of economic or business conditions, including the possibility of a downturn in the U.S. economy. Additional risks and uncertainties not currently known to us or that we currently believe are immaterial also may impair our business, including our results of operations, liquidity and financial position.
Financial Risks
Achieving profitable operations is dependent on several factors.
Our ability to sustain profitability is dependent on many factors, primarily being continued operation under the GEHC Agreement, as well as attaining and maintaining profitability in our IT and equipment segments, as well as the success of our other strategic initiatives.
Risks Related to Our Business
We currently derive a significant amount of our revenue and operating income from the GEHC Agreement.
On May 19, 2010, we signed a sales representation agreement with GEHC. Under the GEHC Agreement, we have been appointed GEHC’s exclusive representative for certain GEHC diagnostic imaging products to specific market segments in the 48 contiguous states of the United States and the District of Columbia. The GEHC Agreement had an initial term of three years commencing July 1, 2010 and has subsequently been extended in 2012, 2014, 2017 and 2021, with the current term through December 31, 2026, subject to GEHC’s right to terminate earlier without cause under certain conditions.
A significant amount of our revenue and operating income arise from activities under this agreement. Moreover, our performance and growth in the professional sales service segment depends partially on the territories, customer accounts and product modalities assigned to us by GEHC, as well as factors beyond our control such as product pricing, availability and delivery schedule, and thus relies on our ability to demonstrate our added value as a channel partner, and on maintaining a positive relationship with GEHC. There is no assurance that the agreement will not be terminated prior to its expiration pursuant to its termination provisions or will be extended beyond the current expiration date. Should GEHC terminate or fail to extend the agreement, it would have a material adverse effect on our financial condition and results of operations.
We face competition from other companies and technologies.
In all segments of our business, we compete with other companies that market technologies, products and services in the global marketplace. We do not know whether these companies, or other potential competitors, may succeed in developing technologies, products or services that are more efficient or effective than those offered by us, rendering our technology and existing products obsolete or non-competitive. Potential new competitors may also have substantially greater financial, manufacturing and marketing resources than those possessed by us. In addition, other technologies or products may be developed that have an entirely different approach or means of accomplishing the intended purpose of our products. Accordingly, the life cycles of our products are difficult to estimate. To compete successfully, we must keep pace with technological advancements, respond to evolving consumer requirements and achieve market acceptance.
7
Data security incidents or disruptions in our information technology systems could damage our business.
We are increasingly dependent on information systems and infrastructure to operate our business. Our ability to effectively manage our business depends on the security, reliability and adequacy of our information systems. We review and enhance our computer systems as well as provide training to our employees in an attempt to prevent unauthorized and unlawful intrusions. Despite our implementation of firewalls, switchgear and other network security measures, our servers, databases and other systems may be vulnerable to various cyber and other security threats, including those caused by computer hackers, physical or electronic break-ins, sabotage, computer viruses, malware, worms, and similar disruptions from unauthorized access and tampering with our computer systems, including through social engineering such as phishing attacks, coordinated denial-of-service attacks and similar incidents. The occurrence of some of these risks may be increased due to the work-from-home arrangements that we have implemented for many of our employees. Significant disruptions in our information technology systems or other data security incidents could adversely affect our business operations and reputation.
We depend on management and other key personnel.
We are dependent on a limited number of key management and technical personnel. The loss of one or more of our key employees may harm our business if we are unable to identify other individuals to provide us with similar services. We do not maintain “key person” insurance on any of our employees. In addition, our success depends upon our ability to attract and retain additional highly qualified management, sales, IT, manufacturing and research and development personnel in our various operations. The competition for IT personnel is intense.
We may not continue to receive necessary clearances or approvals from the US FDA or foreign authorities for our medical devices, which could hinder our ability to market and sell certain products in the relevant markets.
If we modify our medical devices and the modifications significantly affect safety or effectiveness, or if we make a change to the intended use, we will be required to submit a new premarket notification (510(k)) or premarket approval (PMA) application to the FDA. We would not be able to market the modified device in the U.S. until the FDA issues a clearance for the 510(k).
If we offer new products that require 510(k) clearance or a PMA, we will not be able to commercially distribute those products in the U.S. until we receive such clearance or approval. Regulatory agency approval or clearance for a product may not be received or may entail limitations on the device’s indications for use that could limit the potential market for the product. Delays in receipt of, or failure to obtain or maintain, regulatory clearances and approvals, could delay or prevent our ability to market or distribute our products. Such delays could have a material adverse effect on our equipment business.
There are similar medical device regulations or requirements in China, Europe, and other foreign markets where we sell our products. Failure to comply with these regulations and requirements could have a material adverse effect on our equipment business.
If we are unable to comply with applicable governmental regulations, we may not be able to continue certain of our operations.
We are subject to extensive regulation across our business lines.
As a reseller of telecommunication services and network solutions provider, our products and services are subject to federal, state and local regulations. These regulations govern, in part, our rates and the way we conduct our business, including the requirement to offer telecommunications services pursuant to nondiscriminatory rates, terms, and conditions, the obligation to safeguard the confidentiality of customer proprietary network information, as well as the obligation to maintain specialized records and file reports with the Federal Communications Commission and state regulatory authorities. While we believe we are in compliance with laws and regulations in jurisdictions where we do business, we must continue to monitor and assess our compliance.
8
We also must comply with current Good Manufacturing Practice requirements as set forth in the Quality System Regulation to receive US FDA approval to market new products and to continue to market current products. Most states also have similar regulatory and enforcement authority for medical devices.
Our operations in China are also subject to the laws and regulations of the People’s Republic of China with which we must be in compliance in order to conduct these operations.
We are subject to various federal, state and local laws targeting fraud and abuse in the healthcare industry, including anti-kickback and false claims laws.
We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we predict what effect additional governmental regulations or administrative orders, either domestically or internationally, when and if promulgated, would have on our business in the future. We may be slow to adapt, or we may never adapt to changes in existing requirements or adoption of new requirements or policies. We may incur significant costs to comply with laws and regulations in the future and compliance with laws or regulations may create an unsustainable burden on our business.
We have foreign operations and are subject to the associated risks of doing business in foreign countries.
The Company continues to have operations in China. Operating internationally involves additional risks relating to such things as currency exchange rates, different legal and regulatory environments, political, economic risks relating to the stability or predictability of foreign governments, differences in the manner in which different cultures do business, difficulties in staffing and managing foreign operations, differences in financial reporting, operating difficulties, current uncertainties surrounding US tariff policy and other factors. The occurrence of any of these risks, if severe enough, could have an adverse effect on the consolidated financial position, results of operations and cash flows of the Company.
Commercial law is still developing in China and there are limited legal precedents to follow in commercial transactions. There are many tax jurisdictions each of which may have changing tax laws. Applicable taxes include value added taxes (“VAT”), enterprise income tax (“EIT”), and social (payroll) taxes. Regulations are often unclear. Tax declarations (reports) are subject to review and taxing authorities may impose fines, penalties and interest. These facts create risks for our operations in China.
We depend on several suppliers for the supply of certain products.
As a GEHC channel partner, our sales of GEHC products could be negatively impacted by interruptions or delays to equipment installations, production and quality issues, and any customer concerns related to GEHC. Delivery of GEHC equipment may be negatively impacted due to the current supply chain issues especially as it impacts availability of computer chips. With respect to our proprietary medical products we now manufacture our own products primarily through our China based facilities. However, we do depend on certain independent suppliers for parts, components and certain finished goods.
We may not have adequate intellectual property protection.
Our patents and proprietary technology may not be able to prevent competition by others. The validity and breadth of claims in technology patents involve complex legal and factual questions. Future patent applications may not be issued, the scope of any patent protection may not exclude competitors and our patents may not provide competitive advantages to us. Our patents may be found to be invalid and other companies may claim rights in or ownership of the patents and other proprietary rights held or licensed by us. Also, our existing patents may not cover products that we develop in the future. Moreover, when our patents expire, the inventions will enter the public domain. There can be no assurance that our patents will not be violated or that any issued patents will provide protection that has commercial significance. Litigation may be necessary to protect our patent position. Such litigation may be costly and time-consuming, and there can be no assurance that we will be successful in such litigation.
9
The loss or violation of certain of our patents and trademarks could have a material adverse effect upon our business.
Since patent applications in the United States are maintained in secrecy until such patent applications are issued, our current product development may infringe patents that may be issued to others. If our products were found to infringe patents held by competitors, we may have to modify our products to avoid infringement, and it is possible that our modified products would not be commercially successful.
Risks Related to Our Industries
Our growth could suffer if the markets into which we sell products decline, do not grow as anticipated or experience cyclicality.
Our growth depends in part on the growth of the IT and healthcare markets which we serve. In our professional sales services segment, our quarterly sales and profits depend significantly on the volume and timing of delivery of the underlying equipment of the orders we booked, and the delivery of such products is difficult to forecast since it is largely dependent on GEHC. Product demand is dependent upon the customer’s capital spending budget as well as government funding policies, and matters of public policy as well as product cycles and economic downturns that can affect the spending decisions of these entities. These factors could adversely affect our growth, financial position, and results of operations.
Technological change is difficult to predict and to manage.
We face the challenges that are typically faced by companies in the IT and medical device fields. Our products and services may require substantial development efforts and compliance with governmental clearance or approval requirements. We may encounter unforeseen technological or scientific problems that force abandonment or substantial change in the development of a specific product or process.
We are subject to product liability claims and product recalls that may not be covered by insurance.
The nature of our manufacturing operations exposes us to risks of product liability claims and product recalls. Medical devices as complex as ours frequently experience errors or failures, especially when first introduced or when new versions are released.
We currently maintain product liability insurance at $6,000,000 per occurrence and in the aggregate. Our product liability insurance may not be adequate. In the future, insurance coverage may not be available on commercially reasonable terms, or at all. In addition, product liability claims or product recalls could damage our reputation even if we have adequate insurance coverage.
10
Risks Related to our Securities
Our common stock is subject to price volatility.
The market price of our common stock historically has been and may continue to be highly volatile. Our stock price could be subject to wide fluctuations in response to various factors beyond our control, including, but not limited to:
| ● | actual or anticipated fluctuations in our operating results; | |
| ● | overall market fluctuations and domestic and worldwide economic conditions; | |
| ● | medical reimbursement policies; | |
| ● | announcements of technological innovations, new products or pricing by our competitors; | |
| ● | the timing of patent and regulatory approvals; | |
| ● | the timing and extent of technological advancements; | |
| ● | the sales of our common stock by affiliates or other shareholders with large holdings; and | |
| ● | other factors described in the “Risk Factors” and elsewhere in this Report. |
Our future operating results may fall below the expectations of securities industry analysts or investors. Any such shortfall could result in a significant decline in the market price of our common stock. In addition, the stock market has experienced significant price and volume fluctuations that have affected the market price of stocks generally, including our stock, and that often have been unrelated to the operating performance of such companies. These broad market fluctuations may directly influence the market price of our common stock.
We do not intend to pay dividends in the foreseeable future.
We currently do not intend to pay any cash dividends on our common stock in the foreseeable future.
Anti-takeover Risk Factor
The Articles of Incorporation of the Company presently contain certain provisions, such as staggered Board of Directors terms and the ability to issue blank check preferred stock, the lack of stockholder pre-emptive rights, and super majority voting requirements for transactions with substantial shareholders, which may be deemed to be “anti-takeover” in nature in that such provisions may deter, discourage or make more difficult the assumption of control of the Company by another company or person through a tender offer, merger, proxy contest or similar transaction or series of transactions. The overall effects of the “anti-takeover” provisions may be to discourage, make costlier or more difficult, or prevent a future takeover offer, even if shareholders may desire the Company to pursue the takeover offer. These provisions may also increase the possibility that a future bidder for control of the Company will be required to act through arms-length negotiation with the Company’s Board of Directors.
Additional Information
We are subject to the reporting requirements under the Securities Exchange Act of 1934 and are required to file reports and information with the Securities and Exchange Commission (SEC), including reports on the following forms: annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports files or furnished pursuant to Section 13(a) or 15(d) of the Securities Act of 1934.
ITEM 1C – CYBERSECURITY
The President of VasoTechnology and the executive team in our IT business periodically assesses industry best practices, frameworks, and standards so that our practice is up to date for the effective prevention, detection, mitigation, and remediation of cybersecurity incidents. Our cybersecurity risk management program includes the deployment of tools and activities designed to monitor, detect, prevent and analyze current and emerging cybersecurity threats, and plans and strategies to address threats and incidents. Program highlights include:
| ● | Employing a multi-layer strategy of defense designed to ensure the safety, security, and responsible use of information and data. | |
| ● | Monitoring of all IT assets, resources, and data 24-hours per day, 7-days per week, 365-days per year by security operations center (SOC). |
11
| ● | Performing annual testing of the Company’s incident response plan and cybersecurity posture. | |
| ● | Incorporating external expertise to manage the SOC, perform penetration tests, cyber-attack simulation exercises, and log management to review anomalies indicating a possible breach. | |
| ● | Maintaining a business continuity program and cyber insurance. | |
| ● | Performing periodic employee simulated phishing campaigns. | |
| ● | Conducting annual cybersecurity and insider threat training for all employees. |
The President of VasoTechnology is responsible for informing the Audit Committee and the Board of Directors, the CEO and other members of the senior management team on cybersecurity risks on a regular basis, including evolving cybersecurity threats, cybersecurity incidents, cybersecurity technologies and solutions deployed, major cybersecurity risk areas, and policies and procedures to address those risks and cybersecurity incidents, as well as assessments of our cybersecurity program. The President of VasoTechnology also informs the CEO and other members of our senior management team on a more informal basis of all aspects related to cybersecurity risks and incidents. This ensures that the highest levels of management are kept abreast of the cybersecurity posture and potential risks facing us. Any significant cybersecurity matters and strategic risk management decisions related thereto are escalated to the Board of Directors, ensuring that they have comprehensive oversight and can provide guidance on significant cybersecurity issues.
In 2024, the Company achieved its primary cybersecurity risk management objective of no material cybersecurity incidents.
ITEM 2 – PROPERTIES
The Company houses its headquarters and domestic medical device operations at an 8,700 square foot facility located at 137 Commercial Street, Plainview, New York 11803, under a lease with a term that expires on September 30, 2028 and with a base annual rental of approximately $83,000. The Company’s NetWolves unit leases a 16,200 square foot facility in Tampa, Florida, under a lease expiring in June 2027 with an annual rental of approximately $222,000. VHC-IT rents a flexible space, 1,500 square foot facility in Nashville, Tennessee on a month-to-month basis with an annual cost of approximately $37,000. We believe that our current facilities are adequate for foreseeable current and future needs.
We lease our office, engineering and production facilities in China. Specifically, we lease approximately 14,700 square feet of space in Wuxi, China under leases expiring in August 2026, September 2026, and December 2026 at an aggregate annual cost of approximately $73,000. Such leases are renewable upon expiration. We also lease office space of approximately 1,700 square feet to host our software R&D team in Tianjin, China under a lease expiring in February 2026 at an annual coat of approximately $22,000.
ITEM 3 – LEGAL PROCEEDINGS
The Company is currently, and has been in the past, a party to various routine legal proceedings, primarily employee related matters, incident to the ordinary course of business. The Company believes that the outcome of all such pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company.
ITEM 4 – MINE SAFETY DISCLOSURES
Not applicable.
12
PART II
ITEM 5 – MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Our common stock currently trades on the OTC Market (OTCQX) under the symbol VASO. The number of record holders of common stock as of March 25, 2025, was approximately 900, which does not include approximately 8,500 beneficial owners of shares held in the name of brokers or other nominees. The table below sets forth the range of high and low trade prices of the common stock for the fiscal periods specified.
| Year ended December 31, 2024 | Year ended December 31, 2023 | |||||||||||||||
| High | Low | High | Low | |||||||||||||
| First quarter | $ | 0.33 | $ | 0.27 | $ | 0.29 | $ | 0.17 | ||||||||
| Second quarter | $ | 0.31 | $ | 0.21 | $ | 0.26 | $ | 0.21 | ||||||||
| Third quarter | $ | 0.30 | $ | 0.18 | $ | 0.34 | $ | 0.24 | ||||||||
| Fourth quarter | $ | 0.19 | $ | 0.12 | $ | 0.35 | $ | 0.20 | ||||||||
The last bid price of the Company’s common stock on March 25, 2025 was $0.13 per share. Over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
Dividend Policy
We have never paid any cash dividends on our common stock and currently do not intend to pay cash dividends in the foreseeable future.
ITEM 6 – [RESERVED]
ITEM 7– MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward looking statements. See “Forward Looking Statements” and “Risk Factors” in Item 1 (Business) to review certain conditions that we believe could cause results to differ materially from those contemplated by the forward-looking statements.
The following discussion should be read in conjunction with the financial statements and notes thereto included in this Annual Report on Form 10-K.
13
General Overview
Our Business Segments
Vaso Corporation (formerly Vasomedical, Inc.) (“Vaso” or the “Company”) was incorporated in Delaware in July 1987. We principally operate in three distinct business segments in the healthcare equipment and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments.
| ● | IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services; |
| ● | Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GE HealthCare (GEHC) into the health provider middle market; and |
| ● | Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively. |
VasoTechnology
VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC (collectively, “NetWolves”). It currently consists of a managed network and security service division (NetWolves) and a healthcare IT application VAR (value added reseller) division (VasoHealthcare IT). Its current offering includes:
| ● | Managed healthcare software solutions including diagnostic imaging applications (channel partner of select vendors of healthcare IT products). | |
| ● | Managed network infrastructure (routers, switches and other core equipment). | |
| ● | Managed network transport (FCC licensed carrier reselling 175+ facility partners). | |
| ● | Managed network security services. |
VasoTechnology uses a combination of proprietary technology, methodology and best-in-class third-party applications to deliver its value proposition.
VasoHealthcare
VasoHealthcare commenced operations in 2010, in conjunction with the Company’s execution of its exclusive sales representation agreement with GEHC, which at the time was the healthcare business division of the General Electric Company (“GE”), to further the sale of certain medical capital equipment in certain domestic market segments. Its current offering consists of:
| ● | GEHC diagnostic imaging equipment and ultrasound systems. | |
| ● | GEHC service agreements for the above equipment. | |
| ● | GEHC training services for use of the above equipment. | |
| ● | GEHC and third-party financial services for the above equipment. |
VasoHealthcare has built a team of over 80 highly experienced sales professionals who utilize highly focused sales management and analytic tools to manage the complete sales process and to increase market penetration.
14
VasoMedical
The proprietary medical equipment business under VasoMedical traces back to 1995 when the Company began the proprietary Enhanced External Counterpulsation (EECP®) technology in the United States and has since diversified to include other medical hardware and software. Vasomedical Global was formed in 2011 to combine and coordinate the various international operations including design, development, manufacturing, and sales of medical devices and software, while domestic activities are conducted under Vasomedical Solutions. These devices and software primarily consist of cardiovascular diagnostic and therapeutic applications, including:
| ● | Biox® series Holter monitors and ambulatory blood pressure recorders. | |
| ● | ARCS® series analysis, reporting and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription in the form of a SaaS (software as a service) subscription. | |
| ● | MobiCare® multi-parameter wireless vital-sign monitoring system. | |
| ● | EECP® therapy systems for non-invasive, outpatient treatment of ischemic heart disease. |
This segment uses its extensive in-house knowledge and intellectual property for cardiovascular devices and software coupled with its engineering resources to cost effectively create and market its proprietary technology. It sells and services its products to customers in the U.S. and China directly and sells and/or services its products in the international market mainly through independent distributors.
Strategic Plan and Objectives
Our short- and long-term plans for the growth of the Company and to increase stockholder value are as follows:
| ● | Continue to effectively control operating costs in the current inflationary environment. |
| ● | Continue to expand our product and service offerings as well as market penetration in all of our business segments. |
| ● | Maintain and improve business performance in our professional sales service segment by increasing market penetration of the GEHC product portfolio we represent, and possibly building new teams to represent other vendors. |
| ● | Maintain and grow our equipment business by increasing efficiency and continue to transform the operation and explore new revenue models. |
| ● | Continue to seek accretive partnership opportunities. |
| ● | Explore options in capital markets for our stock. |
Results of Operations – For the Years Ended December 31, 2024 and 2023
Total revenues increased by $5,743,000, or 7.1%, to $86,767,000 in the year ended December 31, 2024, from $81,024,000 in the year ended December 31, 2023. We reported net income of $951,000 and $4,805,000 for the years ended December 31, 2024 and 2023, respectively, a decrease of $3,854,000. The decrease in net income was primarily due to higher operating expenses in 2024, partially offset by higher gross profit. Our net income was $0.01 per basic and diluted common share for the year ended December 31, 2024, and $0.03 per basic and diluted common share, for the year ended December 31, 2023.
Revenues
Revenue in the IT segment was $42,954,000 for the year ended December 31, 2024 as compared to $40,371,000 for the prior year, an increase of $2,583,000, or 6.4%, of which $2,684,000 was attributable to an increase in managed network services revenue offset by a decrease of $101,000 in healthcare IT revenues.
Commission revenues in the professional sales service segment increased by $3,515,000, or 9.3%, to $41,335,000 in the year ended December 31, 2024, as compared to $37,820,000 in the year ended December 31, 2023. The increase was primarily due to a higher blended commission rate for equipment delivered in 2024 as well as a higher volume of GEHC equipment delivered in 2024, particularly from the ultrasound program started in 2023. As discussed in Note B to the financial statements, the Company defers recognition of commission revenue until the underlying equipment is delivered. As of December 31, 2024, the Company recorded on its consolidated balance sheet deferred commission revenue of $34,893,000 for this segment (of which $17,821,000 was long-term), an increase of $2,699,000, or 8.4%, compared to $32,194,000 of deferred commission revenue at December 31, 2023 (of which $16,314,000 was long-term). The increase in deferred revenue was due principally to booked orders exceeding equipment deliveries in 2024.
15
Revenue in our equipment segment decreased 12.5% to $2,478,000 for the year ended December 31, 2024 from $2,833,000 for the year ended December 31, 2023, as a result of a $236,000, or 58.9%, decrease in our US operations due to lower ARCS®-cloud software-as-a-service revenues, and lower equipment sales in our China operations due to lower deliveries and the negative effect of foreign exchange rate fluctuations in 2024.
Gross Profit
The Company recorded gross profit of $52,050,000, or 60.0% of revenue, for the year ended December 31, 2024, compared to $50,593,000, or 62.4% of revenue, for the year ended December 31, 2023. The increase of $1,457,000, or 2.9%, was due to a $1,875,000 increase in the professional sales service segment due to higher revenue; a $54,000 decrease in the IT segment due to lower gross margin; and a $364,000 decrease in the equipment segment, as a result of lower revenues and lower gross margin.
IT segment gross profit decreased slightly by $54,000 to $17,605,000, or 41.0% of segment revenues, for the year ended December 31, 2024, as compared to $17,659,000, or 43.7% of segment revenues in the prior year, a decrease of $54,000. This decrease was due to $267,000 lower gross profit from the healthcare IT business resulting from lower revenue and lower gross margin, partially offset by $213,000 higher gross profit from the managed network service business resulting from higher revenue but lower gross margin.
Professional sales service segment gross profit was $32,674,000, or 79.0% of the segment revenues, for the year ended December 31, 2024, an increase of $1,875,000, or 6.1%, from segment gross profit of $30,799,000, or 81.4% of the segment revenue, for the year ended December 31, 2023. The increase in gross profit was due primarily to the increase in the segment revenue as a result of both a higher blended commission rate in 2024 and higher equipment delivery volume. Cost of commissions increased by $1,640,000, or 23.4%, to $8,661,000 for the year ended December 31, 2024, as compared to cost of commissions of $7,021,000 in 2023. The increase was due primarily to the increase in the segment revenue in 2024 as well as the higher commission rate of the ultrasound program. Cost of commissions reflects commission expense associated with recognized commission revenues. Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is earned.
Equipment segment gross profit decreased by $364,000, or 17.0%, to $1,771,000, or 71.5% of equipment segment revenues, for the year ended December 31, 2024, compared to $2,135,000, or 75.4% of equipment segment revenues, for the year ended December 31, 2023, due to lower segment revenue and lower gross profit margin. Equipment segment gross profits are dependent on a number of factors including the mix of products sold, their respective models and average selling prices, the ongoing costs of training, maintenance and servicing, as well as certain fixed period costs, including facilities, payroll and insurance.
Operating Income
Operating income was $285,000 for the year ended December 31, 2024 compared to operating income of $4,195,000 for the year ended December 31, 2023, a decrease of $3,910,000, or 93%. The decrease was primarily attributable to a $1,416,000 increase in corporate expenses associated with the proposed Achari business combination and a $1,294,000 increase in operating loss in the IT segment year over year, from a loss of $466,000 for the year ended December 31, 2023 to a loss of $1,760,000 for the year ended December 31, 2024, due primarily to higher selling, general and administrative (SG&A) costs. Operating income in the professional sales service segment decreased by $367,000 from $7,195,000 for the year ended December 31, 2023 to $6,828,000 for the year ended December 31, 2024, due mainly to higher operating expenses relating to the ultrasound sales program, partially offset by higher gross profit. Operating loss in the equipment segment increased by $833,000, from a loss of $451,000 in the prior year to a loss of $1,254,000 for the year ended December 31, 2024, resulting mainly from lower gross profit and higher SG&A costs.
Selling, general and administrative expenses for the years ended December 31, 2024 and 2023 were $48,984,000, or 56.5% of revenues, and $45,078,000, or 55.6% of revenues, respectively, reflecting an increase of $3,906,000 or 8.7%. The increase in SG&A expenditures in the year ended December 31, 2024 resulted primarily from a $2,242,000 increase in the professional sales service segment attributable mainly to higher sales personnel-related and travel costs, a $1,121,000 increase in the IT segment due to higher personnel and travel costs, and a $352,000 increase in the equipment segment due to higher allowance for credit loss on related party receivables.
Research and development (R&D) expenses of $851,000, or 1% of revenues, for the year ended December 31, 2024 increased by $96,000, or 13%, from $755,000, or 1% of revenues, for the year ended December 31, 2023. The increase was primarily attributable to higher software development costs in our China operations in 2024.
16
Adjusted EBITDA
We define Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), which is a non-GAAP financial measure, as net (loss) income, plus net interest expense (income), tax expense, depreciation and amortization, and non-cash expenses for share-based compensation. Adjusted EBITDA is a metric that is used by the investment community for comparative and valuation purposes. We disclose this metric in order to support and facilitate the dialogue with research analysts and investors.
Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered a substitute for operating income, which we consider to be the most directly comparable GAAP measure. Adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, you should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP. Other companies may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
A reconciliation of net income to Adjusted EBITDA is set forth below:
| (in thousands) | ||||||||
| Year ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Net income | $ | 951 | $ | 4,805 | ||||
| Interest expense (income), net | (1,154 | ) | (858 | ) | ||||
| Income tax expense | 326 | 100 | ||||||
| Depreciation and amortization | 824 | 999 | ||||||
| Share-based compensation | 54 | 48 | ||||||
| Adjusted EBITDA | $ | 1,001 | $ | 5,094 | ||||
Adjusted EBITDA decreased by $4,093,000, to $1,001,000 in the year ended December 31, 2024, from $5,094,000 in the year ended December 31, 2023. The decrease was primarily attributable to lower net income, lower depreciation and amortization and higher net interest income as compared to the prior year. Net income decreased primarily due to higher operating expenses and higher income tax expense in 2024, partially offset by higher revenue and gross profit.
Other Income (Expense), Net
Other income (expense), net for the years ended December 31, 2024 and 2023, was $992,000 and $710,000, respectively, an increase of $282,000. The increase was due primarily to $236,000 higher interest and other income arising from higher money market and US Treasury bill balances during 2024.
Income Tax Expense
During the year ended December 31, 2024, we recorded income tax expense of $326,000, as compared to income tax expense of $100,000 in the year ended December 31, 2023. The Company utilized $5,878,000 and $5,857,000 in net operating loss carryforwards for the years ended December 31, 2024 and 2023, respectively. The increase in income tax expense in 2024 arose primarily from higher state income tax. The Company had net operating loss carryforwards of approximately $19,000,000 at December 31, 2024.
Liquidity and Capital Resources
Cash and Cash Flow – For the year ended December 31, 2024
We have financed our operations and investment activities from working capital. At December 31, 2024, we had cash and cash equivalents of $26,371,000 and working capital of $16,935,000. At March 24, 2025 the Company’s cash and cash equivalents were approximately $32.4 million.
Cash provided by operating activities was $3,281,000 during the year ended December 31, 2024, which consisted of net income after non-cash adjustments of $3,478,000 and changes in operating assets and liabilities of $(197,000). The changes in the account balances primarily reflect increases in deferred revenue of $2,694,000 and accounts payable of $1,511,000, and increases in accrued commissions and accrued liabilities totaling $1,753,000; partially offsetting these changes were increases in accounts and other receivables of $5,065,000, inventories of $574,000, other assets of $524,000 and prepaid expense and other current assets of $475,000.
17
Cash provided by investing activities during the year ended December 31, 2024 was $11,730,000, consisting of $13,756,000 in redemptions of short term investments, offset by $1,453,000 in purchases of equipment and software and $573,000 in working capital loans to Achari.
Cash used in financing activities during the year ended December 31, 2024 was $89,000, consisting of $81,000 in payments of notes and finance leases and $8,000 in shares withheld for payment of payroll taxes.
Liquidity
The Company expects to generate sufficient cash flow from operations to satisfy its obligations at least for the next twelve months. On December 30, 2022, the Company executed a $3.0 million revolving credit agreement with a lending institution. Advances under the agreement bear interest at Wall Street Journal Prime Rate and are secured by substantially all of the assets of the Company. The agreement expired August 31, 2023 and has undergone subsequent renewals through July 31, 2025. The agreement includes certain financial covenants, and the Company was in compliance with such covenants at December 31, 2024, at which time no amounts had been drawn.
Off-Balance Sheet Arrangements
We do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (SPES), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of December 31, 2024, we are not involved in any unconsolidated SPES or other off-balance sheet arrangements.
Effects of Inflation
We believe that inflation and changing prices over the past two years have not had a significant impact on our revenue or on our results of operations.
Critical Accounting Policies and Estimates
Note B of the Notes to Consolidated Financial Statements includes a summary of our significant accounting policies and methods used in the preparation of our financial statements. In preparing these financial statements, we have made our best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. The application of these accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates. Our critical accounting policies and estimates are as follows:
Allowance for Commission Adjustments
In our professional sale service segment, we bill a portion of commissions on the orders we booked in advance of delivery of the underlying equipment. Such amounts are classified in our consolidated balance sheets in accounts receivable and deferred revenue, net of estimated commission adjustments. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense, net of the impact of the estimated commission adjustments, when the associated deferred revenue is recorded. The commission adjustments are based on estimates of future order cancellations, which is calculated based on historical cancellation rates over multiple prior years and applicable credit policies. Such cancellation rates are subject to the uncertainty that future activity cancels at higher or lower rates than the past orders on which the rate was calculated, or that credit policies may change. The Company, based on its current year analysis, did not deem a change in rate necessary as of December 31, 2024. Application of the rates only affects the aforementioned balance sheet accounts, there is no impact to the statement of operations.
18
Valuation Allowance for Deferred Tax Assets
Deferred income taxes are recognized for temporary differences between financial statement and income tax bases of assets and liabilities and loss carry forwards for which income tax benefits are expected to be realized in future years. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. In estimating future tax consequences, we generally consider all expected future events other than an enactment of changes in the tax laws or rates. Deferred tax assets are continually evaluated for realizability. To the extent our judgment regarding the realization of the deferred tax assets changes, an adjustment to the allowance is recorded, with an offsetting increase or decrease, as appropriate, in income tax expense. Such adjustments are recorded in the period in which our estimate as to the realizability of the assets changed that it is “more likely than not” that all of the deferred tax assets will be realized. The “more likely than not” standard is subjective and is based upon our estimate of a greater than 50% probability that the deferred tax asset will be realized.
The primary underlying uncertainty in evaluating the realizability of our deferred tax assets, which are primarily net operating losses, is the need to accurately project taxable income. The Company generated net operating losses in the years ended December 31, 2017, 2018 and 2019. From 2020 to 2022, this trend reversed and the Company generated increasingly higher taxable income, primarily as a result of the professional sales services segment’s growth in orders, revenue, and operating results. As a result of this trend, which we expect to continue, and the extension, through December 31, 2026, of the GEHC Agreement which underlies the performance of the professional sales segment, the Company reviewed positive and negative evidence, including improved historical operating results and the likelihood of such results continuing, and also reviewed its expected taxable income for future periods based on the positive trend in operating results and the extension of the GEHC Agreement to the end of 2026, and concluded that it is more likely than not that approximately $5.4 million of tax benefits related to net operating loss carryforwards will be utilized in the future tax years of 2023 to 2026 and, therefore, reduced its valuation allowance during the year ended December 31, 2022 in accordance with ASC 740. As of December 31, 2024, the Company continues to project sufficient future taxable income requiring no related change to its valuation allowance. In addition, the Company expects to continue providing a valuation allowance on the remaining future tax benefits until it can sustain a level of profitability that demonstrates its ability to utilize the remaining assets, or other significant positive evidence arises that suggests its ability to utilize the remaining assets.
Goodwill and Intangible Assets
Goodwill represents the excess of cost over the fair value of net assets of businesses acquired. The Company accounts for goodwill under the guidance of the ASC Topic 350, “Intangibles: Goodwill and Other”. Goodwill acquired in a purchase business combination and determined to have an indefinite useful life is not amortized, but instead tested for impairment, at least annually, in accordance with this guidance. The recoverability of goodwill is subject to an annual impairment test or whenever an event occurs or circumstances change that would more likely than not result in an impairment. The impairment test is based on the estimated fair value of the underlying businesses and performed in the fourth quarter of each year.
19
We perform either a quantitative or qualitative assessment to assess if the fair value of the respective reporting unit exceeds its carrying value. The qualitative goodwill impairment assessment requires evaluating factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. As part of our goodwill qualitative assessment process for our two applicable reporting units, when utilized, we evaluate various factors that are specific to the reporting unit as well as industry and macroeconomic factors in order to determine whether it is reasonably likely to have a material impact on the fair value of our reporting units. Examples of the factors that are considered include the results of the most recent impairment test, current forecasts, and changes in the strategic outlook or organizational structure of the reporting units. The financial forecasts of the reporting units are compared to the forecasts used in the prior year analysis to determine if management expectations for the business have changed.
When performing the quantitative assessment to calculate the fair value of a reporting unit, we consider both comparative market multiples as well as estimated discounted cash flows for the reporting unit. The significant estimates and assumptions include, but are not limited to, revenue growth rates, operating margins, and future economic and market conditions. The discount rates are based upon industry weighted average cost of capital ranges. As a supplement, we conduct additional sensitivity analysis to assess the risk for potential impairment based upon changes in the key assumptions such as the discount rate, expected long-term growth rate, and cash flow projections. Based upon the completion of our annual test as of December 31, 2024, we determined that there was no impairment of goodwill and that the applicable reporting units’ estimated fair values were substantially in excess of their carrying amounts.
Intangible assets consist of the value of customer contracts and relationships, patent and technology costs, and software. The cost of significant customer-related intangibles is amortized in proportion to estimated total related revenue; cost of other intangible assets is generally amortized on a straight-line basis over the asset’s estimated economic life, which range from five to ten years. The Company capitalizes internal-use software costs incurred during the application development stage. Costs related to preliminary project activities and post implementation activities are expensed as incurred. We evaluate whether events or circumstances have occurred that warrant a revision to the remaining useful lives of intangible assets. In cases where a revision is deemed appropriate, the remaining carrying amounts of the intangible assets are amortized over the revised remaining useful life.
Recently Issued Accounting Pronouncements
Note B of the Notes to Consolidated Financial Statements includes a description of the Company’s evaluation of recently issued accounting pronouncements.
ITEM 8 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements listed in the accompanying Index to Consolidated Financial Statements are filed as part of this report.
ITEM 9A - CONTROLS AND PROCEDURES
Report on Disclosure Controls and Procedures
Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2024 and have concluded that the Company’s disclosure controls and procedures were effective.
20
Management’s Report on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control involves maintaining records that accurately represent our business transactions, providing reasonable assurance that receipts and expenditures of company assets are made in accordance with management authorization, and providing reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be detected or prevented on a timely basis.
Because of its inherent limitations, internal control over our financial statements is not intended to provide absolute guarantee that a misstatement can be detected or prevented in the statements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in condition, or that the degree of compliance with the policies or procedures may deteriorate.
Management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 COSO framework), as required by Rule 13a-15(c) or 15d-15(c) under the Exchange Act. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
Based on this evaluation and those criteria, the Company’s CEO and CFO concluded that the Company’s internal control over financial reporting were effective as of December 31, 2024.
This report does not include an attestation report of the Company’s Independent Registered Public Accounting Firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s Independent Registered Public Accounting Firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only Management’s report in this Annual Report.
Changes in Internal Control over Financial Reporting
For the quarter ended December 31, 2024 there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
ITEM 9B – OTHER INFORMATION
ITEM 9C – DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.
21
PART III
ITEM 10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Directors of the Registrant
As of March 24, 2025, the members of our Board of Directors are:
| Name of Director | Age | Principal Occupation | Director Since | |||
| Joshua Markowitz (2) | 69 | Chairman of the Board and Director | June, 2015 | |||
| Edgar Rios (1) | 72 | Vice Chairman of the Board and Director | February, 2011 | |||
| Jun Ma | 61 | President, Chief Executive Officer and Director | June, 2007 | |||
| Jane Moen | 45 | President, Vasohealthcare and Director | March, 2020 | |||
| Leon Dembo | 70 | Director | April, 2023 | |||
| David Lieberman | 80 | Director | February, 2011 | |||
| Behnam Movaseghi (1) (2) | 71 | Director | July, 2007 |
| (1) | Member of the Audit Committee |
| (2) | Member of the Compensation Committee |
The following is a brief account of the business experience for at least the past five years of our directors:
Joshua Markowitz has been a director since June 2015 and was appointed Chairman of the Board of the Company in August 2016. Mr. Markowitz has been a practicing attorney in the State of New Jersey for in excess of 30 years. He is currently a senior partner in the New Jersey law firm of Markowitz O’Donnell, LLP. Mr. Markowitz was the brother-in-law of Mr. Simon Srybnik (deceased), the former Chairman and director of the Company.
David Lieberman has been a director of the Company since February 2011 and the Vice Chairman of the Board from February 2011 to December 2024. Mr. Lieberman has been a practicing attorney in the State of New York for more than 45 years, specializing in corporation and securities law. He is currently of counsel to the law firm of Ortoli Rosenstadt, LLP, which performs certain legal services for the Company and its subsidiaries. Mr. Lieberman is a former Chairman of the Board of Herley Industries, Inc., which was sold in March 2011.
Jun Ma, PhD, has been a director since June 2007 and was appointed President and Chief Executive Officer of the Company on October 16, 2008. Dr. Ma has held various positions in academia and business, and prior to becoming President and CEO of the Company, had provided technology and business consulting services to several domestic and international companies in aerospace, automotive, biomedical, medical device, and other industries, including Kerns Manufacturing Corp. and Living Data Technology Corp., both of which are stockholders of our Company. Dr. Ma received his PhD degree in mechanical engineering from Columbia University, MS degree in biomedical engineering from Shanghai University, and BS degree in precision machinery and instrumentation from University of Science and Technology of China.
Jane Moen has been a director since March 2020 and an executive officer of the Company since November 2022. Ms. Moen has been President of the Company’s wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare since June 2018 following a remarkable career track record at VasoHealthcare, starting as an Account Manager at the inception of VasoHealthcare in April 2010 and being promoted to Regional Manager in January 2012, Director of Product Business Lines in July 2012 and Vice President of Sales in April 2016. Jane Moen has been in the medical sales industry for over 17 years, having had prior experience with Ledford Medical Sales, Vital Signs, Inc., Pfizer Inc. and Ecolab, Inc.
Leon Dembo has been in the private practice of law for the last 43 years and has been the managing partner of Dembo, Brown & Burns LLP (and its predecessor firm, Dembo & Saldutti LLP), specializing in real estate transactions and commercial litigation, since 1991.
22
Behnam Movaseghi, CPA, has been a director since July 2007. Mr. Movaseghi has been treasurer of Kerns Manufacturing Corporation since 2000, and controller from 1990 to 2000. For approximately ten years prior thereto Mr. Movaseghi was a tax and financial consultant. Mr. Movaseghi is a Certified Public Accountant.
Edgar G. Rios has been a director of the Company since February 2011 and served as Vice Chairman of the Board since January 2025. Mr. Rios was a co-founder, Executive Vice President, General Counsel and Director of AmeriChoice Corporation from its inception in 1989 through its acquisition by UnitedHealthcare in 2002 and continued as a senior executive with United Healthcare through 2007. Prior to co-founding AmeriChoice, Mr. Rios was a senior executive with a number of businesses that provided technology services and non-technology products to government purchasers. Mr. Rios also serves as a member of the Board of Trustees of Meharry Medical School and the Brookings Institution in Washington DC; and as a director of the Los Padres Foundation in Virginia. Mr. Rios holds a J.D. from Columbia University Law School and an A.B. from Princeton University.
Committees of the Board of Directors
Audit Committee and Audit Committee Financial Expert
The Board has a standing Audit Committee. The Board has affirmatively determined that each director who serves on the Audit Committee is independent, as the term is defined by applicable Securities and Exchange Commission (“SEC”) rules. During the year ended December 31, 2024, the Audit Committee consisted of Edgar Rios, committee chair, and Behnam Movaseghi. The members of the Audit Committee have substantial experience in assessing the performance of companies, gained as members of the Company’s Board of Directors and Audit Committee, as well as by serving in various capacities in other companies or governmental agencies. As a result, they each have an understanding of financial statements. The Board believes that Behnam Movaseghi meets the qualifications to be deemed to be the “financial expert” on this committee.
The Audit Committee regularly meets with our independent registered public accounting firm without the presence of management.
The Audit Committee operates under a charter approved by the Board of Directors. The Audit Committee charter is available on our website.
Compensation Committee
Our Compensation Committee annually establishes, subject to the approval of the Board of Directors and any applicable employment agreements, the compensation that will be paid to our executive officers during the coming year, and administers our stock-based benefit plans. During the year ended December 31, 2024, the Compensation Committee consisted of Joshua Markowitz, committee chair, and Behnam Movaseghi. Neither of these persons has been officers or employees of the Company at the time of his position on the committee, or, except as otherwise disclosed, had any relationship requiring disclosure herein.
The Compensation Committee operates under a charter approved by the Board of Directors. The Compensation Committee charter is available on our website.
Nominating Committee
The Company does not have a standing nominating committee. The entire Board of Directors serves as the Company’s nominating committee. The following members of the Board are not independent under the standards applicable to service on the nominating committee: Jun Ma, Jane Moen and David Lieberman.
MEETINGS OF THE BOARD OF DIRECTORS AND COMMITTEES
During the year ended December 31, 2024 there were:
| ● | 8 meetings of the Board of Directors | |
| ● | 4 meetings of the Audit Committee | |
| ● | 2 meetings of the Compensation Committee |
23
Delinquent Section 16(a) Reports
Section 16(a) of the Exchange Act requires directors, executive officers and persons who beneficially own more than 10% of our common stock (collectively, “Reporting Persons”) to file initial reports of ownership and reports of changes in ownership of our common stock with the SEC. Reporting Persons are required by SEC regulations to furnish us with copies of all Section 16(a) reports they file. To our knowledge, based solely on our review of the copies of such reports received or written representations from certain Reporting Persons that no other reports were required, we believe that during the year ended December 31, 2024 all Reporting Persons timely complied with all applicable filing requirements.
Corporate Governance - Code of Ethics
We have adopted a Corporate Code of Business Ethics (the “Code”) that applies to all employees, including our principal executive officer, principal financial officer, and directors of the Company. A copy of the Code can be found on our website, www.vasocorporation.com. The Code is broad in scope and is intended to foster honest and ethical conduct, including accurate financial reporting, compliance with laws and the like. If any substantive amendments are made to the Code or if there is any grant of waiver, including any implicit waiver, from a provision of the Code to our Chief Executive Officer or Chief Financial Officer, we will disclose the nature of such amendment or waiver in a Current Report on Form 8-K. Our Code includes an Insider Trading Policy and procedures governing the purchase, sale, and/or other dispositions of the Company’s securities by directors, officers, employees, and the Company itself, that the Company believes are reasonably designed to promote compliance with insider trading laws, rules, and regulations. In addition, it is the Company’s policy to comply with applicable securities and state laws, including insider trading laws, when engaging in transactions in the Company’s securities. A copy of the Company’s Insider Trading Policy is filed as Exhibit 19 to this Annual Report.
Executive Officers of the Registrant
As of March 24, 2025 our executive officers are:
| Name of Officer | Age | Position held with the Company | ||
| Jun Ma, PhD | 61 | President, Chief Executive Officer | ||
| Jane Moen | 45 | President of VasoHealthcare, Chief Operating Officer | ||
| Peter C. Castle | 56 | President of VasoTechnology | ||
| Jonathan P. Newton | 64 | Chief Financial Officer, Treasurer and Secretary |
Peter Castle was a director from August 2010 to December 2019 and served as Chief Operating Officer of the Company after the NetWolves acquisition from June 2015 until January 2025. Prior to the acquisition, Mr. Castle was the President and Chief Executive Officer of NetWolves Network Services, LLC, where he has been employed since 1998. At NetWolves, Mr. Castle also held the position of Chief Financial Officer from 2001 until October 2009, Vice President of Finance since January 2000, Controller from August 1998 until December 1999 and Treasurer and Secretary from August 1999.
Jonathan P. Newton served as Chief Financial Officer of the Company from September 1, 2010 to September 8, 2011, Vice President of Finance and Treasurer until December 10, 2019, Co-Chief Financial Officer and Treasurer until January 2025, and is currently Chief Financial Officer, Treasurer and Secretary. From June 2006 to August 2010, Mr. Newton was Director of Budgets and Financial Analysis for Curtiss-Wright Flow Control. Prior to his position at Curtiss-Wright Flow Control, Mr. Newton was Vasomedical’s Director of Budgets and Analysis from August 2001 to June 2006. Prior positions included Controller of North American Telecommunications Corp., Accounting Manager for Luitpold Pharmaceuticals, positions of increasing responsibility within the internal audit function of the Northrop Grumman Corporation and approximately three and one half years as an accountant for Deloitte Haskins & Sells, during which time Mr. Newton became a Certified Public Accountant. Mr. Newton holds a B.S. in Accounting from SUNY at Albany, and a B.S. in Mechanical Engineering from Hofstra University.
24
ITEM 11 - EXECUTIVE COMPENSATION
The following table sets forth the annual and long-term compensation of our Chief Executive Officer and each of our most highly compensated officers who were serving as executive officers at the end of the last completed fiscal year for services rendered for the years ended December 31, 2024 and 2023.
Summary Compensation Table
| Name and Principal Position | Year | Salary ($) | Bonus ($) | Stock Awards ($) | Option Awards ($) | Non-Equity Incentive Plan Compensation ($) | Nonqualified Deferred Compensation Earnings ($) | All Other Compensation($) (1)(2)(3) | Total ($) | ||||||||||||||||||||||||||
| Jun Ma, PhD | 2024 | 500,000 | 200,000 | 56,635 | 756,635 | ||||||||||||||||||||||||||||||
| Chief Executive Officer | 2023 | 500,000 | 230,000 | 191,610 | 921,610 | ||||||||||||||||||||||||||||||
| Jane Moen | 2024 | 350,000 | 300,000 | 61,379 | 711,379 | ||||||||||||||||||||||||||||||
| President of Vasohealthcare, Chief Operating Officer | 2023 | 350,000 | 330,000 | 49,438 | 729,438 | ||||||||||||||||||||||||||||||
| Peter C. Castle | 2024 | 350,000 | - | 12,000 | 362,000 | ||||||||||||||||||||||||||||||
| President of VasoTechnology | 2023 | 350,000 | 80,000 | 12,000 | 442,000 | ||||||||||||||||||||||||||||||
| (1) | Jun Ma received $48,000 in lodging and car allowance, $6,100 in 401(k) matching contributions, and $2,535 in Company-paid life insurance in 2024; and $137,218 in tax gross-up on vested stock, $48,000 in lodging and car allowance, $3,857 in 401(k) matching contributions, and $2,535 in Company-paid life insurance in 2023. |
| (2) | Jane Moen received $50,726 in tax gross-up on vested stock, $6,053 in Company-provided vehicle benefit, and $4,600 in 401(k) matching contributions in 2024; and $38,502 in tax gross-up on vested stock, $8,686 in Company-provided vehicle benefit, and $2,250 in 401(k) matching contributions in 2023. |
| (3) | Peter Castle received $12,000 in car allowance in 2024 and 2023, respectively. |
Pay versus Performance
In accordance with rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we are providing the following disclosure regarding executive compensation for our principal executive officer (“PEO”) and Non-PEO named executive officers (“NEOs”) and Company performance for the years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown.
| Year | Summary Compensation Table Total for PEO (1) | Compensation Actually Paid to PEO (1)(2)(3) | Average Summary Compensation Table Total for Non-PEO NEOs (1) | Average Compensation Actually Paid to Non-PEO NEOs (1)(2)(4) | Value of Initial Fixed $100 Investment Based on TSR (5) | Net Income | ||||||||||||||||||
| 2024 | $ | 756,635 | $ | 756,635 | $ | 536,690 | $ | 536,690 | $ | 240 | $ | 1,301,000 | ||||||||||||
| 2023 | $ | 921,610 | $ | 971,610 | $ | 585,719 | $ | 606,719 | $ | 620 | $ | 4,805,000 | ||||||||||||
| 2022 | $ | 805,323 | $ | 975,323 | $ | 466,632 | $ | 493,632 | $ | 340 | $ | 11,294,000 | ||||||||||||
| (1) | The PEO for all years was Jun Ma. The non-PEO NEOs for all years were Jane Moen and Peter Castle. |
| (2) | The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnotes 3 and 4 below. Equity values are calculated in accordance with FASB ASC Topic 718. |
| (3) | To calculate the amounts of Compensation Actually Paid to the PEO in each of 2024, 2023 and 2022, the following adjustments were made to the PEO’s Summary Compensation Table Total for each respective year: |
| a. | Year 2024: |
| i. | None |
| b. | Year 2023: |
| i. | We added $50,000, reflecting, as of the applicable vesting date, the change in the fair value during 2023 of equity-based awards granted to the PEO before 2023 that vested during 2023. |
25
| c. | Year 2022: |
| i. | We added $120,000, reflecting the change in the fair value during 2022 of equity-based awards granted to the PEO before 2022 that were outstanding and unvested as of the end of 2022; and |
| ii. | we added $50,000, reflecting, as of the applicable vesting date, the change in the fair value during 2022 of equity-based awards granted to the PEO before 2022 that vested during 2022. |
| (4) | To calculate the amounts of Compensation Actually Paid, on average, to our non-PEO NEOs in each of 2024, 2023 and 2022, the following adjustments were made to the Average Summary Compensation Table Total for Non-PEO NEOs for each respective year: |
| a. | Year 2024: |
| i. | None |
| b. | Year 2023: |
| i. | We added $14,000, reflecting the change in the fair value during 2023 of equity-based awards granted to the non-PEO NEOs before 2023 that were outstanding and unvested as of the end of 2023; and |
| ii. | we added $7,000, reflecting, as of the applicable vesting date, the change in the fair value during 2023 of equity-based awards granted to the non-PEO NEOs before 2023 that vested during 2023. |
| c. | Year 2022: |
| i. | We added $24,000, reflecting the change in the fair value during 2022 of equity-based awards granted to the non-PEO NEOs before 2022 that were outstanding and unvested as of the end of 2022; and |
| ii. | we added $3,000, reflecting, as of the applicable vesting date, the change in the fair value during 2022 of equity-based awards granted to the non-PEO NEOs before 2022 that vested during 2022. |
| (5) | The values disclosed in this TSR column represent the measurement period value of an investment of $100 in our common stock as of December 31, 2021, and then valued again on each of December 31, 2022, December 31, 2023 and December 31, 2024. Historical stock performance is not necessarily indicative of future stock performance. |
Outstanding Equity Awards at Last Fiscal Year End
Equity awards, including stock options, are not granted in anticipation of the release of material non-public information, and the release of material non-public information is not timed on the basis of option or other equity grant dates. There were no outstanding equity awards at December 31, 2024.
Employment Agreements
On May 10, 2019, the Company modified its Employment Agreement with its President and Chief Executive Officer, Dr. Jun Ma, to provide for a five-year term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond May 31, 2026. The Employment Agreement provides for annual compensation of $500,000. Dr. Ma shall be eligible to receive a bonus for each fiscal year during the employment term. The amount and the occasion for payment of such bonus, if any, shall be at the discretion of the Board of Directors. Dr. Ma shall also be eligible for an award under any long-term incentive compensation plan and grants of options and awards of shares of the Company’s stock, as determined at the Board of Directors’ discretion. The Employment Agreement further provides for reimbursement of certain expenses and for severance payments in the event of the termination of his employment in the following circumstances: (i) if his employment is terminated by the Company without “Cause” or by Dr. Ma for “Good Reason”, he is entitled to receive continued salary for 24 months and a bonus payment in the amount he would have otherwise received had employment not terminated; provided that if the remaining term of the agreement is less than 24 months, the duration of the continued salary shall instead be the greater of 12 months or the remaining term of the agreement. In addition, any unvested options or shares will immediately vest; (ii) If his employment is terminated due to death or disability, his beneficiary will receive 12 months of his salary; and (iii) if a “Change in Control” occurs, and his employment is terminated within 2 years thereafter by the Company without cause or by Dr. Ma for good reason, he is entitled to receive a lump sum payment equal to 2.5 times the sum of (a) his salary plus (b) the average of the annual bonuses paid to Dr. Ma in the three-year period immediately prior to termination.
26
Under Section 280G of the Internal Revenue Code, if a severance payment made in connection with a change of control to a “disqualified individual”, which includes Dr. Ma, exceeds 3 times that person’s average annualized compensation for the five preceding tax years (“parachute payment”) the paying corporation is denied any deduction for employee compensation on any excess parachute payments, and the recipient is subject to a nondeductible 20% excise tax on such excess parachute payment (in addition to income taxes). To provide a means to avoid this disadvantageous tax treatment the employment agreements contain a “cut back” provision that applies if the severance payment would exceed the 280G limits; in that event, the Corporation will compute the after-tax net amount the employee would receive after paying all taxes (including the excise tax) on the severance payment provided for by the Employment Agreement (the “Original Severance Amount”). If the Original Severance Amount is less than or equal to the net amount the employee would receive if the severance payment was reduced to the highest amount at which no excise tax would be imposed, then the employee will receive the reduced amount so that the excise tax is avoided.
On December 31, 2022, the Company executed an Employment Agreement with the President of its VasoHealthcare subsidiary, Ms. Jane Moen, to provide for a twenty-seven month initial term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond December 31, 2026. The Employment Agreement provides for annual base compensation of $350,000. Ms. Moen shall be eligible to receive bonuses for each fiscal year during the employment term. The amount and the occasion for payment of such bonuses, if any, shall be based on employment status and achieving certain operating targets. Ms. Moen shall also be eligible for an award under any long-term incentive compensation plan and grants of options and awards of shares of the Company’s stock, as determined at the Board of Directors’ discretion. The Employment Agreement further provides for reimbursement of certain expenses and for severance payments in the event of the termination of her employment in the following circumstances: (i) if her employment is terminated by the Company without “Cause” or by Ms. Moen for “Good Reason”, she is entitled to $20,000 per month for 24 months and a pro-rated bonus payment in the amount she would have otherwise received had employment not terminated. In addition, any unvested options or shares will immediately vest; (ii) if her employment is terminated due to death or disability, her beneficiary will receive 6 months of her salary.
For purposes of the Employment Agreements, “Cause” means the employee’s conviction of or pleading guilty or no contest to, a felony or crime of moral turpitude, willful refusal to perform his or her duties that results in material economic harm to the Company or breach of the confidentiality and non-solicitation/non-compete clauses of his or her Employment Agreement; and “Good Reason” means, in each case without the employee’s consent, a reduction in salary, a failure to pay when due salary, bonus or vested stock, or the failure of a successor to assume in writing the obligations of the Agreements. In addition, under the Employment Agreements, a change of control occurs when one of the following events takes place: (i) any person or group acting in concert acquires more than 50% of the total fair market value or voting power of the Company’s stock, excluding any acquisition of stock from the company, an affiliate, an employee benefit plan or broad-based employee benefit plan sponsored by the Company; a majority of the members of the Board is replaced during any 30 month period (excluding directors whose nomination was endorsed by a majority of the members of the Board, excluding any new director who became a director as a result of a contested election; a merger, consolidation, reorganization or similar transaction unless the owners of the Company’s securities immediately prior to the transaction continue to own 70% of the post-transaction entity in substantially the same proportions or in a transaction in which no person acquires more than 30% of the voting power of the Company’s outstanding securities; or a complete liquidation, dissolution, sale or other disposition of substantially all of the assets of the Company except to a subsidiary or an affiliate.
401(k) Plan
The Company maintains a defined contribution plan to provide retirement benefits for its employees - the Vaso Corporation 401(k) Plan adopted in April 1997. As allowed under Section 401(k) of the Internal Revenue Code, the plan provides tax-deferred salary deductions for eligible employees. Employees are eligible to participate in the next quarter enrollment period after employment under the Vaso Corporation Plan. Participants may make voluntary contributions to the plan up to 80% of their compensation under the Vaso Corporation Plan. In the years ended December 31, 2024 and 2023 the Company made discretionary contributions of approximately $345,000 and $234,000, respectively, to match a percentage of employee contributions.
Director’s Compensation
Each of the non-employee directors receives an annual fee of $50,000 as well as a fee of $2,500 for each Board of Directors and Committee meeting attended, except for the Chairman who receives a flat fee of $180,000 per annum. Committee chairs receive an additional annual fee of $5,000. 150,000 shares of restricted common stock, vesting immediately, was granted to Leon Dembo for joining the Board of Directors.
| Fees Earned or Paid in Cash | Stock Awards (1) | Option Awards | Non-equity Incentive Plan Compensation | Nonqualified Deferred Compensation Earnings | All Other Compensation (2) | Total | ||||||||||||||||||||||
| Name | ($) | ($) | ($) | ($) | ($) | ($) | ($) | |||||||||||||||||||||
| Leon Dembo | 70,000 | 19,500 | - | - | - | 6,500 | 96,000 | |||||||||||||||||||||
| David Lieberman | 70,000 | - | - | - | - | 25,624 | 95,624 | |||||||||||||||||||||
| Joshua Markowitz | 180,000 | - | - | - | - | - | 180,000 | |||||||||||||||||||||
| Behnam Movaseghi | 85,000 | - | - | - | - | - | 85,000 | |||||||||||||||||||||
| Edgar Rios | 85,000 | - | - | - | - | - | 85,000 | |||||||||||||||||||||
| (1) | Represents grant date fair value of restricted stock award. |
| (2) | Represents tax gross-up for Mr. Dembo and health benefit premiums for Mr. Lieberman. |
27
ITEM 12 - SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The following table sets forth the beneficial ownership of shares of our common stock as of March 25, 2025 of (i) each person known by us to beneficially own 5% or more of the shares of outstanding common stock, based solely on filings with the SEC, (ii) each of our executive officers and directors, and (iii) all of our executive officers and directors as a group. Except as otherwise indicated, all shares are beneficially owned, and investment and voting power is held by the persons named as owners. To our knowledge, except under community property laws or as otherwise noted, the persons and entities named in the table have sole voting and sole investment power over their shares of our common stock. Unless otherwise indicated, each beneficial owner listed below maintains a mailing address of c/o Vaso Corporation, 137 Commercial Street, Plainview, New York 11803.
| Name of Beneficial Owner | Common Stock Beneficially Owned (1) | % of Common Stock (2) | ||||||
| Joshua Markowitz ** (3) | 56,088,318 | 31.92 | % | |||||
| Jun Ma, PhD ** | 10,498,146 | 5.98 | % | |||||
| Peter Castle ** | 3,125,000 | 1.78 | % | |||||
| Edgar Rios ** | 1,625,000 | * | ||||||
| Jane Moen ** | 1,605,087 | * | ||||||
| David Lieberman ** | 1,599,200 | * | ||||||
| Jonathan Newton ** | 1,275,000 | * | ||||||
| Michael J. Beecher ** | 1,240,400 | * | ||||||
| Behnam Movaseghi ** | 1,189,404 | * | ||||||
| Leon Dembo ** | 150,000 | * | ||||||
| ** Directors and executive officers as a group (10 persons) | 78,395,555 | 44.62 | % | |||||
| * | Less than 1% of the Company’s common stock |
| (1) | No officer or director owns more than one percent of the issued and outstanding common stock of the Company unless otherwise indicated. |
| (2) | Applicable percentages are based on 175,696,311 shares of common stock outstanding as of March 25, 2025, adjusted as required by rules promulgated by the SEC. |
| (3) | Joshua Markowitz is the record holder of 350,000 shares of our common stock. Additionally, 55,738,318 shares are held in trust funds of which Mr. Markowitz is the sole trustee. |
28
Equity Compensation Plan Information
The Company previously issued equity compensation under the Vasomedical, Inc. 2010 Stock Plan (the “2010 Plan”) and the Vasomedical, Inc. 2013 Stock Plan (the “2013 Plan”). The 2010 Plan and the 2013 Plan have expired, and no additional shares may be issued under those plans. The Company currently maintains the Vasomedical 2016 Stock Plan (the “2016 Plan”), which will expire in 2026, and the Vaso Corporation 2019 Stock Plan (the “2019 Plan”). The Company may issue stock grants under the 2016 Plan and the 2019 Plan at the discretion of our Board of Directors or its Compensation Committee. The value of stock issued under these plans is not less than the fair market value on the date of the grant. The participants in these plans are officers, directors, employees, and consultants of the Company and its subsidiaries and affiliates.
| Plan category | (a) Number of securities to be issued upon exercise of outstanding options, warrants and rights | (b) Weighted- average exercise price of outstanding options, warrants and rights | (c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | |||||||||
| Equity Compensation plans approved by security holders | - | $ | 0.00 | - | ||||||||
| Equity Compensation plans not approved by security holders (1) | 796,666 | $ | 0.00 | 8,881,361 | ||||||||
| Total | 796,666 | 8,881,361 | ||||||||||
| (1) | Includes 16,666 shares of restricted common stock granted, but unvested, under the 2013 Plan, and 780,000 shares of restricted common stock granted, but unvested, under the 2016 Plan. 531,361 shares and 8,350,000 shares remain available for future grants under the 2016 Plan and 2019 Plan, respectively. |
See Note O to the Consolidated Financial Statements for description of the material features of our current stock plans not approved by stockholders.
ITEM 13 - CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Director Independence
We have adopted the NASDAQ Stock Market’s standards for determining the independence of directors.
The Board of Directors has assessed the independence of each non-employee director under the independence standards of the NASDAQ Stock Market, and has affirmatively determined that a majority of our directors are independent under the independence standards generally applicable to directors: Mr. Rios, Mr. Markowitz, Mr. Dembo and Mr. Movaseghi. In addition, each member of the Audit Committee and Compensation Committee have also been determined to be independent under the independence standards applicable to service on those committees. The Company does not have a standing nominating committee. The entire Board of Directors serves as the Company’s nominating committee. The following members of the Board are not independent under the standards applicable to service on the nominating committee: Jun Ma, Jane Moen and David Lieberman.
29
We expect each director to attend every meeting of the Board and the committees on which he serves as well as the annual meeting. In the year ended December 31, 2024, all directors attended at least 75% of the meetings of the Board and the committees on which they served.
Related Party Transactions
There were no transactions in which the Company or any of its subsidiaries was a participant, the amount involved exceeded the lesser of (i) $120,000 or (ii) 1% of the Company’s average total assets as of the end of its prior 2 fiscal years, and any Director, Director nominee, executive officer, or any of their immediate family members had a direct or indirect material interest reportable under applicable SEC rules, nor are there any such transactions currently proposed.
ITEM 14 - PRINCIPAL ACCOUNTING FEES AND SERVICES
UHY LLP, as our independent registered public accounting firm, performed the audits of our consolidated financial statements for the years ended December 31, 2024 and 2023. The following table sets forth all fees for such periods:
| 2024 | 2023 | |||||||
| Audit fees (1) | $ | 377,095 | $ | 291,400 | ||||
| Audit-related fees | - | - | ||||||
| Tax fees | - | - | ||||||
| All other fees | - | - | ||||||
| Total | $ | 377,095 | $ | 291,400 | ||||
| (1) | Includes $114,000 and $31,400 in 2024 and 2023, respectively, for review of SEC filings associated with the Achari business combination. |
The Audit Committee has adopted a policy that requires advance approval of all audit, audit-related, tax services, and other services performed by the Company’s independent auditor. Accordingly, the Audit Committee must approve the permitted service before the independent auditor is engaged to perform it. In accordance with such policies, the Audit Committee approved 100% of the services relative to the above fees.
30
PART IV
ITEM 15 – EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
Financial Statements and Financial Statement Schedules
| (1) | See Index to Consolidated Financial Statements on page F-1 at beginning of attached financial statements. |
| (a) | Exhibits |
31
| (e) | 2016 Stock Plan (9) | ||
| (f) | 2019 Stock Plan (10) | ||
| (g) | Redacted Employment Agreement entered into as of October 1, 2022 between Vaso Corporation and Jane Moen | ||
| (19) | (a) | Insider Trading Policy | |
| (21) | Subsidiaries of the Registrant |
| Name | State of Incorporation | Percentage Owned by Company | ||
| Vaso Diagnostics, Inc. | New York | 100% | ||
| VasoMedical, Inc. | Delaware | 100% | ||
| Vasomedical Global Corp. | New York | 100% | ||
| Vasomedical Solutions, Inc. | New York | 100% | ||
| VasoHealthcare IT Corp. | Delaware | 100% | ||
| VasoTechnology, Inc. | Delaware | 100% | ||
| NetWolves Network Services LLC | Florida | 100% | ||
| EECP Global Corporation | New York | 49% | ||
| Fast Growth Enterprises Limited | British Virgin Islands | 100% |
| (31) | Certification Reports pursuant to Securities Exchange Act Rule 13a - 14 | ||
| (32) | Certification Reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) | ||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | ||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | ||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101) |
| (1) | Incorporated by reference to Registration Statement on Form S-18, No. 33-24095. |
| (2) | Incorporated by reference to Registration Statement on Form S-1, No. 33-46377 (effective 7/12/94). |
| (3) | Incorporated by reference to Report on Form 8-K dated June 21, 2010. |
| (4) | Incorporated by reference to Report on Form 8-K/A dated May 19, 2010 and filed November 9, 2010. |
| (5) | Incorporated by reference to Report on Form 8-K dated June 20, 2012. |
| (6) | Incorporated by reference to Report on Form 8-K dated March 21, 2011. |
| (7) | Incorporated by reference to Report on Form 10-Q for the quarter ended September 30, 2016. |
| (8) | Incorporated by reference to Report on Form 10-Q for the quarter ended September 30, 2013. |
| (9) | Incorporated by reference to Report on Form 10-Q for the quarter ended June 30, 2016. |
| (10) | Incorporated by reference to Report on Form 10-K for the year ended December 31, 2019. |
32
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, we have duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on the 31st day of March 2025.
VASO CORPORATION
| By: | /s/ Jun Ma | |
| Jun Ma | ||
| President, Chief Executive Officer, | ||
| and Director (Principal Executive Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on March 31, 2025, by the following persons in the capacities indicated:
| /s/ Jun Ma | President, Chief Executive Officer | |
| Jun Ma | and Director (Principal Executive Officer) | |
| /s/ Jonathan Newton | Chief Financial Officer (Principal Financial and Accounting Officer) | |
| Jonathan Newton | ||
| /s/ Joshua Markowitz | Director (Chairman of the Board) | |
| Joshua Markowitz | ||
| /s/ Edgar Rios | Director (Vice Chairman of the Board) | |
| Edgar Rios | ||
| /s/ Jane Moen | Director | |
| Jane Moen | ||
| /s/ David Lieberman | Director | |
| David Lieberman | ||
| /s/ Behnam Movaseghi | Director | |
| Behnam Movaseghi | ||
| /s/ Leon Dembo | Director | |
| Leon Dembo |
33
Vaso Corporation and Subsidiaries
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
For the years ended December 31, 2024 and 2023
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders
and Board of Directors of
Vaso Corporation and Subsidiaries
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Vaso Corporation and Subsidiaries (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive income, changes in stockholders’ equity and cash flows for the years then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements referred to above present fairly, in all material respect, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relates to an account or disclosure that is material to the financial statements and (2) involved especially challenging, subjective, or complex judgments. The communication of the critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.
F-2
To the Stockholders
and Board of Directors of
Vaso Corporation and Subsidiaries
Page Two
Critical Audit Matter - Revenue recognized from sales commission with General Electric Healthcare (GEHC)
As discussed in Notes A and B to the financial statements, the Company, through its wholly owned subsidiary VasoHealthcare (VHC), was appointed the exclusive representative for the sale of GEHC’s diagnostics imaging equipment to specific market segments and recognized sales commission revenue when the underlying equipment and services have been delivered or completed by GEHC. VHC has total sales commission revenue of approximately $41.3 million for the year ended December 31, 2024, which is concentrated solely with GEHC.
We identified the testing of sales commission revenue generated from GEHC as a critical audit matter. Specifically, the sales commission revenue, along with the associated deferred revenue, accounts receivable and commissions payable for VHC, is calculated through complicated formulas including order data from various files obtained from GEHC monthly and is stored in a spreadsheet file based on the master agreement and various subsequent amendments between GEHC and the Company. The audit of the spreadsheet file was challenging and complex as it requires significant efforts from auditors due to the volume of data, size of the file, and complexity of formulas within the spreadsheet file.
How the Critical Audit Matter Was Addressed in the Audit
During the audit, we obtained an understanding of the design and implementation of the internal control over the revenue recognition process and over the spreadsheet file. For selected orders based on our judgment, we tested the Company’s master file for completeness, traced the source data to the various files that are further directly confirmed with GEHC on sales orders, delivery and payments received, tested the formulas for its accuracy and reasonableness and agreed the commission rates to the agreements between GEHC and further confirmed with GEHC as to which sales region achieved the target order volume. Furthermore, for a selection of orders, we verified the delivery date and customer order value to the source documents.
Critical Audit Matter – Valuation of Goodwill
As discussed in Note B to the financial statements, the Company evaluates goodwill for impairment at the reporting unit level at least annually, or more frequently if events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The goodwill balance as of December 31, 2024 was $15.6 million. The Company considers potential impairment by comparing the fair value of a reporting unit to its carrying value. Fair value is estimated by management using both comparable market multiples and estimated discounted cash flow models. No impairment charge was recorded for the year ended December 31, 2024.
We identified goodwill impairment as a critical audit matter because of the significant judgments made by management to estimate the fair value of the reporting units. This required a high degree of auditor judgment and an increased extent of effort, including our need to involve valuation specialists, when performing audit procedures to evaluate the reasonableness of inputs into the quantitative models driven by management’s estimates and assumptions. Significant management estimates include forecasted revenue growth rates, forecasted gross profit, operating expenses and discount rates.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures performed to evaluate the reasonableness of management’s estimates and assumptions included assessing the methodologies used by the Company and testing the significant assumptions used in the quantitative models. We compared current and prior year forecasts prepared by management to historical revenue and gross profit to evaluate the reasonableness of the assumptions and to evaluate management’s ability to accurately forecast future revenues and gross profit. We evaluated historical trends in assessing the reasonableness of growth rate assumptions and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting units that would result from changes in these assumptions. We performed procedures to verify the mathematical accuracy of the calculations used by management. We involved our valuation specialists to assist us in identifying the significant assumptions underlying the models, assessing the rationale and supporting documents related to these assumptions, and determining the appropriateness and reasonableness of the methodologies employed. Furthermore, we assessed the appropriateness of the disclosures in the financial statements.
/s/
We have served as the Company’s auditor since 2022.
March 31, 2025
F-3
Vaso Corporation and Subsidiaries
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
| December 31, 2024 | December 31, 2023 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Short-term investments | ||||||||
| Accounts and other receivables, net of an allowance for credit losses and commission adjustments of $ | ||||||||
| Receivables due from related parties | ||||||||
| Inventories, net | ||||||||
| Deferred commission expense | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Property and equipment, net of accumulated depreciation of $ | ||||||||
| Operating lease right of use assets | ||||||||
| Goodwill | ||||||||
| Intangibles, net | ||||||||
| Other assets, net | ||||||||
| Investment in EECP Global | ||||||||
| Deferred tax assets, net | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued commissions | ||||||||
| Accrued expenses and other liabilities | ||||||||
| Finance lease liabilities - current | ||||||||
| Operating lease liabilities - current | ||||||||
| Sales tax payable | ||||||||
| Income taxes payable | - | |||||||
| Deferred revenue - current portion | ||||||||
| Notes payable - current portion | ||||||||
| Due to related party | ||||||||
| Total current liabilities | ||||||||
| LONG-TERM LIABILITIES | ||||||||
| Notes payable, net of current portion | ||||||||
| Finance lease liabilities, net of current portion | - | |||||||
| Operating lease liabilities, net of current portion | ||||||||
| Deferred revenue, net of current portion | ||||||||
| Other long-term liabilities | ||||||||
| Total long-term liabilities | ||||||||
| COMMITMENTS AND CONTINGENCIES (NOTE Q) | ||||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Preferred stock, $ | ||||||||
| Common stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Treasury stock, at cost, | ( | ) | ||||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-4
Vaso Corporation and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(in thousands, except per share data)
| Year ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenues | ||||||||
| Managed IT systems and services | $ | $ | ||||||
| Professional sales services | ||||||||
| Equipment sales and services | ||||||||
| Total revenues | ||||||||
| Cost of revenues | ||||||||
| Cost of managed IT systems and services | ||||||||
| Cost of professional sales services | ||||||||
| Cost of equipment sales and services | ||||||||
| Total cost of revenues | ||||||||
| Gross profit | ||||||||
| Operating expenses | ||||||||
| Selling, general and administrative | ||||||||
| Research and development | ||||||||
| Business combination transaction costs | ||||||||
| Total operating expenses | ||||||||
| Operating income | ||||||||
| Other (expense) income | ||||||||
| Interest and financing costs | ( | ) | ( | ) | ||||
| Interest and other income, net | ||||||||
| Loss on disposal of fixed assets | ( | ) | ( | ) | ||||
| Total other income, net | ||||||||
| Income before income taxes | ||||||||
| Income tax expense | ( | ) | ( | ) | ||||
| Net income | ||||||||
| Other comprehensive income | ||||||||
| Foreign currency translation loss | ( | ) | ( | ) | ||||
| Comprehensive income | $ | $ | ||||||
| Income per common share | ||||||||
| - basic and diluted | $ | $ | ||||||
| Weighted average common shares outstanding | ||||||||
| - basic | ||||||||
| - diluted | ||||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-5
Vaso Corporation and Subsidiaries
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands)
| Accumulated | ||||||||||||||||||||||||||||||||
| Other | Total | |||||||||||||||||||||||||||||||
| Common Stock | Treasury Stock | Additional | Accumulated | Comprehensive | Stockholders’ | |||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Paid-in-Capital | Deficit | Loss | Equity | |||||||||||||||||||||||||
| Balance at January 1, 2023 | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||
| Share-based compensation | ||||||||||||||||||||||||||||||||
| Shares withheld for employee tax liability | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Foreign currency translation loss | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Net income | - | - | ||||||||||||||||||||||||||||||
| Balance at December 31, 2023 | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||
| Balance at January 1, 2024 | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||
| Retirement of treasury shares | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
| Share-based compensation | ||||||||||||||||||||||||||||||||
| Shares withheld for employee tax liability | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Foreign currency translation loss | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Net income | - | - | ||||||||||||||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-6
Vaso Corporation and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year ended | ||||||||
| December 31, | ||||||||
| 2024 | 2023 | |||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | $ | ||||||
| Adjustments to reconcile net income to net cash provided by operating activities | ||||||||
| Depreciation and amortization | ||||||||
| Deferred income taxes | ||||||||
| Loss from investment in EECP Global | ||||||||
| Provision for credit losses and commission adjustments | ||||||||
| Write-off of Achari loan | ||||||||
| Share-based compensation | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts and other receivables | ( | ) | ||||||
| Due from related parties | ( | ) | ( | ) | ||||
| Inventories | ( | ) | ||||||
| Deferred commission expense | ( | ) | ( | ) | ||||
| Prepaid expenses and other current assets | ( | ) | ( | ) | ||||
| Other assets, net | ( | ) | ( | ) | ||||
| Accounts payable | ||||||||
| Accrued commissions | ( | ) | ||||||
| Accrued expenses and other liabilities | ( | ) | ||||||
| Sales tax payable | ( | ) | ||||||
| Income taxes payable | ||||||||
| Deferred revenue | ||||||||
| Due to related party | ( | ) | ||||||
| Other long-term liabilities | ( | ) | ||||||
| Net cash provided by operating activities | ||||||||
| Cash flows from investing activities | ||||||||
| Purchases of equipment and software | ( | ) | ( | ) | ||||
| Loan to Achari | ( | ) | ||||||
| Purchases of short-term investments | ( | ) | ||||||
| Redemption of short-term investments | ||||||||
| Net cash provided by (used in) investing activities | ( | ) | ||||||
| Cash flows from financing activities | ||||||||
| Payroll taxes paid by withholding shares | ( | ) | ( | ) | ||||
| Repayment of notes payable and finance lease obligations | ( | ) | ( | ) | ||||
| Net cash used in financing activities | ( | ) | ( | ) | ||||
| Effect of exchange rate differences on cash and cash equivalents | ||||||||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | ( | ) | ||||||
| Cash and cash equivalents - beginning of year | ||||||||
| Cash and cash equivalents - end of year | $ | $ | ||||||
| SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION | ||||||||
| Interest paid | $ | $ | ||||||
| Income taxes paid | $ | $ | ||||||
| SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES | ||||||||
| Initial recognition of operating lease right of use asset and liability | $ | $ | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
F-7
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
NOTE A – DESCRIPTION OF BUSINESS
Vaso Corporation was incorporated in Delaware in July 1987. For most of its history, the Company was a single-product company designing, manufacturing, marketing and servicing its proprietary Enhanced External Counterpulsation, or EECP®, therapy systems, mainly for the treatment of angina. In 2010 it began to diversify its business operations. The Company changed its name to Vaso Corporation in 2016 to more accurately reflect the diversified nature of its business mixture, and continues to use the original name VasoMedical for its proprietary medical device subsidiary. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries.
Overview
Vaso Corporation (“the “Company”) principally operates in three distinct business segments in the healthcare equipment and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments.
| ● | IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc. (“VasoTechnology”) primarily focuses on healthcare IT and managed network technology services; |
| ● | Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GE HealthCare Technologies, Inc. (“GEHC”) into the health provider middle market; and |
| ● | Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively. |
VasoTechnology
VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”). VasoTechnology currently consists of a managed network and security service division, NetWolves, and a healthcare IT application VAR (value added reseller) division, VasoHealthcare IT.
In June 2014, the Company began its IT segment business by executing the Value Added Reseller Agreement (“VAR Agreement”) with GEHC to become a national value added reseller of GEHC Digital’s software solutions such as Picture Archiving and Communication System (“PACS”), Radiology Information System (“RIS”), and related services, including implementation, training, management and support. This business focuses primarily on customer segments currently served by VasoHealthcare on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp. (“VHC IT”), was formed to conduct the healthcare IT business. The VAR Agreement with GEHC was terminated in 2021.
In May 2015, the Company further expanded its IT segment business by acquiring NetWolves. NetWolves designs and delivers multi-network and multi-technology solutions as a managed network provider, and provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution.
VasoHealthcare
In May 2010, the Company launched its Professional Sales Service business through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, which was appointed by GEHC as its exclusive representative for the sale of select GEHC diagnostic imaging equipment to specific market segments in the 48 contiguous states of the United States and the District of Columbia. The original agreement (“GEHC Agreement”) has been extended several times and currently expires December 31, 2026, subject to earlier termination under certain conditions. The scope of the agreement was expanded in 2023 to include ultrasound systems.
F-8
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
VasoMedical
The proprietary medical equipment business under VasoMedical traces back to 1995 when the Company began the proprietary Enhanced External Counterpulsation (EECP®) technology in the United States and has since diversified to include other medical hardware and software. Vasomedical Global was formed in 2011 to combine and coordinate the various international operations including design, development, manufacturing, and sales of medical devices and software, while domestic activities are conducted under Vasomedical Solutions.
Over the last 10+ years the Company’s Equipment business has been significantly expanded from the original EECP®-only operations. In September 2011, the Company acquired Fast Growth Enterprises Limited (“FGE”), a British Virgin Islands company, which owned or controlled two Chinese operating companies - Life Enhancement Technology Ltd. (“LET”) and Biox Instruments Co. Ltd. (“Biox”) - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Biox was a variable interest entity (“VIE”) controlled by FGE through certain contracts and an option to acquire all the shares of Biox by FGE’s wholly owned subsidiary Gentone. In March 2019 Gentone exercised its option to acquire all of the shares of Biox. In August 2014, the Company, through Gentone, acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (“Genwell”), which was formed in China in 2010 to develop the MobiCare® wireless multi-parameter patient monitoring system and holds intellectual property rights for this system. As a result, the Company has expanded its equipment products portfolio to include Biox® series ambulatory patient monitoring systems, ARCS® series cloud-based software and algorithm for ECG and blood pressure monitoring and analysis, and the MobiCare® patient monitoring device.
In April 2014, the Company
entered into a cooperation agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (“PSK”) of Chongqing, China,
the leading manufacturer of external counter pulsation, or ECP, therapy systems in China, to form a joint venture company, VSK Medical
Limited (“VSK”), a Cayman Islands company, for the global marketing, sale and advancement of ECP therapy technology. The Company
owned
Termination of Achari Business Combination Agreement
As previously disclosed,
the Company entered into a business combination agreement (the “Business Combination Agreement”), dated as of December
6, 2023, with Achari Ventures Holdings Corp. I, a Delaware corporation (“Achari”), and Achari Merger Sub, Inc., a
Delaware corporation and a wholly owned subsidiary of Achari. On September 17, 2024, Vaso provided to Achari a notice of termination
of the Business Combination Agreement. Business combination transaction costs presented in the Consolidated Statements of Operations
and Comprehensive Income include investment banking and other advisory and legal costs incurred associated with the Business
Combination Agreement, as well as the write-off of $
F-9
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
A summary of the significant accounting policies consistently applied in the preparation of the consolidated financial statements are as follows:
Principles of Consolidation
The consolidated financial statements include the accounts of Vaso Corporation, its wholly-owned subsidiaries, and the accounts of the companies over which we exercise control. Significant intercompany balances and transactions have been eliminated.
Use of Estimates
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions relate to estimates of commission adjustments due to order cancellations, collectability of accounts receivable, the realizability of deferred tax assets, stock-based compensation, values and lives assigned to acquired intangible assets, fair value of reporting units in connection with goodwill impairment test, the adequacy of inventory reserves, variable consideration, and allocation of contract transaction price to performance obligations. Actual results could differ from those estimates.
Revenue Recognition
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. ASU 2014-09 replaced most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers, and establishes disclosure requirements which are more extensive than those required under prior U.S. GAAP. Generally, we recognize revenue under Topic 606 for each of our performance obligations either over time (generally, the transfer of a service) or at a point in time (generally, the transfer of a good) as follows:
| ● | VasoTechnology |
Revenue relating to recurring managed network and voice services provided by NetWolves, for which the customer has unlimited access to such services throughout the contract term, are thus recognized as provided on a monthly basis (“over time”). Non-recurring charges related to the provision of such services are recognized in the period provided (“point in time”). In the IT VAR business, software system installations are recognized upon verification of installation and expiration of an acceptance period (“point in time”). Monthly post-implementation customer support – a stand-ready obligation of the Company to provide maintenance services if and when needed - provided under such installations, as well as software solutions offered under a monthly Software as a Service (“SaaS”) fee basis, for which the customer has unlimited access to such services throughout the contract term, are thus recognized monthly over the contract term (“over time”).
F-10
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
| ● | VasoHealthcare |
Commission revenue is recognized when the underlying equipment has been delivered by GEHC and accepted at the customer site in accordance with the terms of the specific sales agreement (“point in time”).
| ● | VasoMedical |
In the United States, we recognized revenue from the sale of our medical equipment in the period in which we deliver the product to the customer (“point in time”). Revenue from the sale of our medical equipment to international markets is recognized upon shipment of the product to a common carrier, as are supplies, accessories and spare parts delivered in both domestic and international markets (“point in time”). Revenue from the provision of ARCS® under a monthly SaaS fee basis, for which the customer has unlimited access to such services throughout the contract term, are thus recognized monthly over the contract term (“over time”). The Company also recognizes revenue from the maintenance of its medical products either on a time and material as-billed basis (“point in time”) or through the sale of a service contract, where revenue is recognized ratably over the contract term (“over time”).
Disaggregation of Revenue
The following tables present revenues disaggregated by our business operations and timing of revenue recognition:
| (in thousands) | ||||||||||||||||||||||||||||||||
| Year Ended December 31, 2024 | Year Ended December 31, 2023 | |||||||||||||||||||||||||||||||
| Professional sales service | Equipment | Professional sales service | Equipment | |||||||||||||||||||||||||||||
| IT segment | segment | segment | Total | IT segment | segment | segment | Total | |||||||||||||||||||||||||
| Network services | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||
| Software sales and support | ||||||||||||||||||||||||||||||||
| Commissions | ||||||||||||||||||||||||||||||||
| Medical equipment sales | ||||||||||||||||||||||||||||||||
| Medical equipment service | ||||||||||||||||||||||||||||||||
| $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||
| Year Ended December 31, 2024 | Year Ended December 31, 2023 | |||||||||||||||||||||||||||||||
| Professional sales service | Equipment | Professional sales service | Equipment | |||||||||||||||||||||||||||||
| IT segment | segment | segment | Total | IT segment | segment | segment | Total | |||||||||||||||||||||||||
| Revenue recognized over time | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||
| Revenue recognized at a point in time | ||||||||||||||||||||||||||||||||
| $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||
F-11
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
Transaction Price Allocated to Remaining Performance Obligations
As of December 31, 2024, the
aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed
contracts approximates $
| (in thousands) | ||||||||||||||||
| Fiscal years of revenue recognition | ||||||||||||||||
| 2025 | 2026 | 2027 | Thereafter | |||||||||||||
| Unfulfilled performance obligations | $ | $ | $ | $ | ||||||||||||
As of December 31, 2023, the
aggregate amount of transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied) for executed
contracts approximated $
Contract Balances
Contract receivables include
trade receivables, net and long-term receivables (recorded in Other assets in the consolidated balance sheets). Contract liabilities arise
in our IT, VasoHealthcare, and VasoMedical businesses. In our VHC IT business, payment arrangements with clients typically include an
initial payment due upon contract signing and milestone-based payments based upon product delivery and go-live, as well as post go-live
monthly payments for subscription and support fees. Customer payments received, or receivables recorded, in advance of go-live and customer
acceptance, where applicable, are deferred as contract liabilities. Such amounts aggregated approximately $
In our VasoHealthcare business,
we bill a portion of commissions on the orders we booked in advance of delivery of the underlying equipment. Such amounts aggregated approximately
$
In our VasoMedical business,
we bill amounts for post-delivery services and varying duration service contracts in advance of performance. Such amounts aggregated approximately
$
The following table summarizes the Company’s contract receivable and contract liability balances:
| (in thousands) | ||||||||
| 2024 | 2023 | |||||||
| Contract receivables - January 1 | ||||||||
| Contract receivables - December 31 | ||||||||
| Increase (decrease) | ( | ) | ||||||
| Contract liabilities - January 1 | ||||||||
| Contract liabilities - December 31 | ||||||||
| Increase (decrease) | ( | ) | ||||||
The increase in contract receivables
and liabilities in 2024 is due primarily to higher orders in our VasoHealthcare business. During the years ended December 31, 2024 and
2023, we recognized approximately $
F-12
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
Costs to Obtain or Fulfill a Contract
Topic 606 requires that incremental costs of obtaining a contract are recognized as an asset and amortized to expense in a pattern that matches the timing of the revenue recognition of the related contract. We have determined the only significant incremental costs incurred to obtain contracts with customers within the scope of Topic 606 are certain sales commissions paid to associates. In addition, the Company elected the practical expedient to recognize the incremental costs of obtaining a contract when incurred for contracts where the amortization period for the asset the Company would otherwise have recognized is one year or less.
Under Topic 606, sales commissions
applicable to service contracts exceeding one year have been capitalized and amortized ratably over the term of the contract. In our VHC
IT business, commissions allocable to multi-year subscription contracts or multi-year post-contract support performance obligations are
amortized to expense ratably over the terms of the multi-year periods. VHC IT commissions allocable to other elements are charged to expense
at go-live or customer acceptance. In our professional sales services segment, commissions paid to our sales force are deferred until
the underlying equipment is accepted by the customer. We recognized approximately $
At December 31, 2024 and 2023,
our consolidated balance sheets include approximately $
Significant Judgments when Applying Topic 606
Contract transaction price is allocated to performance obligations using estimated stand-alone selling price. Judgment is required in estimating stand-alone selling price for each distinct performance obligation. We determine stand-alone selling price maximizing observable inputs such as stand-alone sales when they exist or substantive renewal price charged to clients. In instances where stand-alone selling price is not observable, we utilize an estimate of stand-alone selling price based on historical pricing and industry practices.
Certain revenue we record in our professional sales service segment contains an estimate for variable consideration. Due to the tiered structure of our commission rate, which increases as annual targets are achieved, under Topic 606 we record revenue and deferred revenue at the rate we expect to be achieved by year end. We base our estimate of variable consideration on historical results of previous years’ achievement under the GEHC agreement. Such estimate is reviewed each quarter and adjusted as necessary. In addition, the Company records commissions for arranging financing at an estimated rate which is subject to later revision based on certain factors. The Company recognized changes in revenue associated with revisions to variable consideration for previously completed performance obligations were minimal for the years ended December 31, 2024 and 2023.
The Company also records commission adjustments to contract liabilities in its professional sales service segment based on estimates of future order cancellations. Such cancellations also result in adjustments to the related capitalized cost to obtain or fulfill a contract.
Shipping and Handling Costs
All shipping and handling expenses are charged to cost of sales. Amounts billed to customers related to shipping and handling costs are included as a component of sales.
Research and Development
Research and development costs attributable to development are expensed as incurred.
F-13
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
Share-Based Compensation
The Company complies with ASC Topic 718, “Compensation – Stock Compensation” (“ASC 718”), which requires all companies to recognize the cost of services received in exchange for equity instruments to be recognized in the financial statements based on their grant date fair values. The Company applies an estimated forfeiture rate to the grant date fair value to determine the annual compensation cost of share-based payment arrangements with employees. The forfeiture rate is estimated based primarily on job title and prior forfeiture experience. The Company did not grant any awards to non-employees during the years ended December 31, 2024 and 2023.
During the year ended December
31, 2024, the Company granted
During the year ended December
31, 2023, the Company granted
The Company did not grant any stock options during the years ended December 31, 2024 or 2023, nor were any options exercised during such periods. No options were outstanding at December 31, 2024 or 2023.
Share-based compensation expense
recognized for the years ended December 31, 2024 and 2023 was $
Cash and Cash Equivalents
Cash and cash equivalents represent cash and short-term, highly liquid investments either in certificates of deposit, U.S. Treasury bills, money market funds, or investment grade commercial paper issued by major corporations and financial institutions that generally have maturities of three months or less from the date of acquisition.
Short-term investments
The Company’s short-term investments
consist of six-month U.S. Treasury bills and bank deposits with yields based on underlying debt and equity securities. The Company had
no short-term investments at December 31, 2024. The U.S. Treasury bills are classified as held-to-maturity and are carried at amortized
cost of approximately $
Financial Instruments
The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
F-14
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows:
Level 1
Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
Level 2
Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 3
Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
The carrying amount of assets and liabilities including cash and cash equivalents, short-term investments, accounts receivable, prepaids, accounts payable, accrued expenses and other current liabilities approximated their fair value as of December 31, 2024 and 2023, due to the relative short maturity of these instruments. Property and equipment, intangible assets, capital lease obligations, and goodwill are not required to be re-measured to fair value on a recurring basis. These assets are evaluated for impairment if certain triggering events occur. If such evaluation indicates that impairment exists, the respective asset is written down to its fair value.
The following table presents information about the Company’s assets measured at fair value as of December 31, 2024 and 2023:
| (in thousands) | ||||||||||||||||
| Quoted Prices in Active Markets for Identical Assets | Significant Inputs | Significant Unobservable Inputs | Balance as of December 31, | |||||||||||||
| (Level 1) | (Level 2) | (Level 3) | 2024 | |||||||||||||
| Assets | ||||||||||||||||
| Cash equivalents invested in money market funds and treasury bills | $ | $ | $ | $ | ||||||||||||
| Quoted Prices in Active Markets for Identical Assets | Significant Other Observable Inputs | Significant Unobservable Inputs | Balance as of December 31, | |||||||||||||
| (Level 1) | (Level 2) | (Level 3) | 2023 | |||||||||||||
| Assets | ||||||||||||||||
| Cash equivalents invested in money market funds and treasury bills | $ | $ | $ | $ | ||||||||||||
| Bank deposits (included in short term investments) | ||||||||||||||||
| $ | $ | $ | $ | |||||||||||||
F-15
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
Accounts Receivable, net
The Company’s accounts receivable are due from customers to whom we sell our products and services, distributors engaged in the distribution of our products and from GEHC. Credit is extended based on evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are generally due 30 to 90 days from shipment and services provided and are stated at amounts due from customers net of allowances for credit losses, returns, term discounts and other allowances. Accounts that are outstanding longer than the contractual payment terms are considered past due. Estimates are used in determining the allowance for credit losses based on the Company’s historical collections experience, current trends and future economic conditions, credit policy and a percentage of its accounts receivable by aging category. In determining these percentages, the Company reviews historical write-offs of its receivables. The Company also looks at the credit quality of its customer base as well as changes in its credit policies. The Company continuously monitors collections and payments from our customers, and writes off receivables when all efforts at collection have been exhausted. While credit losses have historically been within expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same credit loss rates that it has in the past.
The changes in the Company’s allowance for doubtful accounts and commission adjustments are as follows:
| (in thousands) | ||||||||
| Year ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Beginning Balance | $ | $ | ||||||
| Provision for losses on accounts receivable | ||||||||
| Direct write-offs, net of recoveries | ( | ) | ( | ) | ||||
| Commission adjustments | ||||||||
| Ending Balance | $ | $ | ||||||
Concentrations of Credit Risk
We market our equipment and
IT software solutions principally to hospitals, diagnostic imaging centers and physician private practices. We perform credit evaluations
of our customers’ financial condition and, as a result, believe that our receivable credit risk exposure is limited. For the years
ended December 31, 2024 and 2023, no customer in our equipment or IT segment accounted for 10% or more of revenues or accounts receivable.
In our professional sales service segment,
The Company maintains cash
balances in certain U.S. financial institutions which exceed the Federal Depository Insurance Corporation (“FDIC”) coverage
of $
Inventories
The Company values inventories in the equipment segment at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. The Company regularly reviews inventory quantities on hand, particularly raw materials and components, and records a provision for excess and slow moving inventory based primarily on existing and anticipated design and engineering changes to its products as well as forecasts of future product demand.
In our IT Segment, we purchase computer hardware and software for specific customer requirements and value such inventories using the specific identification method.
F-16
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
Property and Equipment
Property and equipment, including
assets under finance leases, are stated at cost less accumulated depreciation and amortization. Major improvements are capitalized and
minor replacements, maintenance and repairs are charged to expense as incurred. Upon retirement or disposal of assets, the cost and related
accumulated depreciation are removed from the consolidated balance sheets. Depreciation is expensed over the estimated useful lives of
the assets, which range from
Impairment of Long-lived Assets
The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. If required, the Company compares the estimated fair value determined by either the undiscounted future net cash flows or appraised value to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. assets were determined to be impaired as of December 31, 2024 and 2023.
Goodwill and Intangible Assets
Goodwill represents the excess of cost over the fair value of net assets of businesses acquired. The Company accounts for goodwill under the guidance of the ASC Topic 350, “Intangibles: Goodwill and Other”. Goodwill acquired in a purchase business combination and determined to have an indefinite useful life is not amortized, but instead tested for impairment, at least annually, in accordance with this guidance. The recoverability of goodwill is subject to an annual impairment test or whenever an event occurs or circumstances change that would more likely than not result in an impairment. The impairment test is based on the estimated fair value of the underlying businesses and performed in the fourth quarter of each year.
We perform either a quantitative or qualitative assessment to assess if the fair value of the respective reporting unit exceeds its carrying value. The qualitative goodwill impairment assessment requires evaluating factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. As part of our goodwill qualitative assessment process for our two applicable reporting units, when utilized, we evaluate various factors that are specific to the reporting unit as well as industry and macroeconomic factors in order to determine whether it is reasonably likely to have a material impact on the fair value of our reporting units. Examples of the factors that are considered include the results of the most recent impairment test, current forecasts, and changes in the strategic outlook or organizational structure of the reporting units. The financial forecasts of the reporting units are compared to the forecasts used in the prior year analysis to determine if management expectations for the business have changed.
When performing the quantitative assessment to calculate the fair value of a reporting unit, we consider both comparative market multiples as well as estimated discounted cash flows for the reporting unit. The significant estimates and assumptions include, but are not limited to, revenue growth rates, operating margins, and future economic and market conditions. The discount rates are based upon industry weighted average cost of capital ranges. As a supplement, we conduct additional sensitivity analysis to assess the risk for potential impairment based upon changes in the key assumptions such as the discount rate, expected long-term growth rate, and cash flow projections. Based upon the completion of our annual test as of December 31, 2024 and 2023, we determined that there was no impairment of goodwill and that the applicable reporting units’ estimated fair values were substantially in excess of their carrying amounts.
F-17
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
Intangible
assets consist of the value of customer contracts and relationships, patent and technology costs, and software. The cost of significant
customer-related intangibles is amortized in proportion to estimated total related revenue; cost of other intangible assets is generally
amortized on a straight-line basis over the asset’s estimated economic life, which range from
Deferred Revenue
Amounts billable under the agreement with GEHC in advance of delivery of the underlying equipment are recorded initially as deferred revenue, and commission revenue is subsequently recognized as customer acceptance of such equipment is reported to us by GEHC. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.
In our equipment segment, we record revenue on extended service contracts ratably over the term of the related service contracts.
Income Taxes
Deferred income taxes are
recognized for temporary differences between financial statement and income tax bases of assets and liabilities and loss carry-forwards
for which income tax benefits are expected to be realized in future years. A valuation allowance is established, when necessary, to reduce
deferred tax assets to the amount expected to be realized. In estimating future tax consequences, we generally consider all expected future
events other than an enactment of changes in the tax laws or rates. Deferred tax assets are continually evaluated for the expected realization.
To the extent our judgment regarding the realization of the deferred tax assets changes, an adjustment to the allowance is recorded, with
an offsetting increase or decrease, as appropriate, in income tax expense. Such adjustments are recorded in the period in which our estimate
as to the realization of the assets changed that it is “more likely than not” that all of the deferred tax assets will be
realized. The “realization” standard is subjective and is based upon our estimate of a greater than
The Company also complies with the provisions of ASC Topic 740, “Income Taxes”, which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by the relevant taxing authority based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement with the relevant taxing authority. Derecognition of a tax benefit previously recognized results in the Company recording a tax liability that reduces ending retained earnings. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of December 31, 2024 and 2023. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. amounts were accrued for the payment of interest and penalties at December 31, 2024 and 2023. Generally, the Company is no longer subject to income tax examinations by major domestic taxing authorities for years before 2020. Under the China tax regulatory framework, there is no statute of limitations on examination of tax filings by tax authorities. However, we understand that the general practice of the China tax regulatory authority is to audit going back no more than five years. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.
Foreign Currency Translation Gain (Loss) and Comprehensive Income
When the Company
operates in a foreign jurisdiction that has a functional currency other than the U.S. dollar, the value of foreign denominated
assets and liabilities are translated into US dollars using published exchange rates in effect at the consolidated balance sheet
date. Equity accounts are translated at historical rates except for the changes in accumulated deficit during the year as
the result of the income statement translation process. Revenues and expenses and cash flows are translated using a weighted average
exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other
comprehensive income (loss) on the accompanying consolidated balance sheets. For the years ended December 31, 2024 and
2023, other comprehensive income includes losses of $
F-18
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
Net Income Per Common Share
Basic income per common share was computed based on the weighted average number of common shares outstanding, including vested restricted shares, without inclusion of potentially dilutive common stock. Diluted earnings per common share is based on the weighted average number of common and potential dilutive common shares outstanding.
Diluted
earnings per share were computed based on the weighted average number of common shares outstanding, including vested restricted shares,
plus all potentially dilutive common shares.
| (in thousands) | ||||||||
| Year ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Basic weighted average shares outstanding | ||||||||
| Dilutive effect of unvested restricted shares | ||||||||
| Diluted weighted average shares outstanding | ||||||||
common stock equivalents were excluded from the computation of diluted earnings per share for the years ended December 31, 2024 and 2023.
Reclassifications
Certain SG&A costs in 2023 were reclassified to business combination transaction costs within the Consolidated Statements of Operations and Comprehensive Income to conform with the current year presentation.
Recently Adopted Accounting Standards
The Company adopted ASU 2023-07, Segment Reporting (Topic 280), Improvement to Reportable Segment Disclosures as of December 31, 2024. This ASU, which requires retrospective application, is effective for annual reporting periods beginning with the year ended December 31, 2024, and interim periods beginning with the three months ending March 31, 2025. It requires additional disclosure of significant reportable segment expenses that are regularly provided to the chief operating decision-maker (“CODM”) and included within the Company’s measure of segment profit or loss. Such additional disclosures are included within Note C of the Consolidated Financial Statements.
Recently Issued Accounting Standards To Be Adopted
The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequence of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change. New pronouncements assessed by the Company recently are discussed below:
In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740), Improvement to Income Tax Disclosures, which requires enhanced income tax disclosures, including disaggregation of information in the rate reconciliation table and disaggregated information related to income taxes paid. The ASU is effective for annual reporting periods beginning with the year ending December 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its Consolidated Financial Statements.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure of disaggregated information about certain income statement line items in the notes to the financial statements. The ASU is effective for annual reporting periods beginning with the year ending December 31, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its Consolidated Financial Statements.
NOTE C – SEGMENT REPORTING
The Company operates its
business in
F-19
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
The
chief operating decision maker is the Company’s Chief Executive Officer, who, in conjunction with upper management, evaluates segment
performance based on operating income and Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization – defined
as net (loss) income, plus net interest expense (income), tax expense, depreciation and amortization, and non-cash expenses for share-based
compensation). Administrative functions such as finance and human resources are centralized and related expenses allocated to each segment.
Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as
well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment
revenues.
| (in thousands) | ||||||||
| Year ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenues from external customers | ||||||||
| IT | $ | $ | ||||||
| Professional sales service | ||||||||
| Equipment | ||||||||
| Total revenues | $ | $ | ||||||
| Gross Profit | ||||||||
| IT | $ | $ | ||||||
| Professional sales service | ||||||||
| Equipment | ||||||||
| Total gross profit | $ | $ | ||||||
| Significant segment expenses | ||||||||
| Selling, general & administrative | ||||||||
| IT | $ | $ | ||||||
| Professional sales service | ||||||||
| Equipment | ||||||||
| Corporate | ||||||||
| Total selling, general and administrative | $ | $ | ||||||
| Other segment items | ||||||||
| IT | $ | $ | ||||||
| Equipment | ||||||||
| Corporate | ||||||||
| Total other segment items | $ | $ | ||||||
| Operating income (loss) | ||||||||
| IT | $ | ( | ) | $ | ( | ) | ||
| Professional sales service | ||||||||
| Equipment | ( | ) | ( | ) | ||||
| Corporate | ( | ) | ( | ) | ||||
| Total operating income | $ | $ | ||||||
| Depreciation and amortization | ||||||||
| IT | $ | $ | ||||||
| Professional sales service | ||||||||
| Equipment | ||||||||
| Corporate | - | - | ||||||
| Total depreciation and amortization | $ | $ | ||||||
| Capital expenditures | ||||||||
| IT | $ | $ | ||||||
| Professional sales service | ||||||||
| Equipment | ||||||||
| Corporate | - | - | ||||||
| Total capital expenditures | $ | $ | ||||||
F-20
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
| December 31, 2024 | December 31, 2023 | |||||||
| Identifiable Assets | ||||||||
| IT | $ | $ | ||||||
| Professional sales service | ||||||||
| Equipment | ||||||||
| Corporate | ||||||||
| Total assets | $ | $ | ||||||
Other
segment items include research and development costs and business combination transaction costs. For the years ended December 31, 2024
and 2023, GEHC accounted for
Our revenues were derived from the following geographic areas:
| (in thousands) | ||||||||
| Year ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Domestic (United States) | $ | $ | ||||||
| Non-domestic (foreign) | ||||||||
| $ | $ | |||||||
NOTE D – ACCOUNTS AND OTHER RECEIVABLES
The following table presents information regarding the Company’s accounts and other receivables as of December 31, 2024 and 2023:
| (in thousands) | ||||||||
| December 31, 2024 | December 31, 2023 | |||||||
| Trade receivables | $ | $ | ||||||
| Allowance for credit losses and commission adjustments | ( | ) | ( | ) | ||||
| Accounts and other receivables, net | $ | $ | ||||||
Trade receivables include amounts due for shipped products and services rendered. Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.
Allowance for credit losses and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from estimated future changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.
F-21
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
NOTE E – INVENTORIES
Inventories, net of reserves, consisted of the following:
| (in thousands) | ||||||||
| December 31, 2024 | December 31, 2023 | |||||||
| Raw materials | $ | $ | ||||||
| Work in process | ||||||||
| Finished goods | ||||||||
| $ | $ | |||||||
At
December 31, 2024 and 2023, the Company maintained reserves for slow moving inventories of $
NOTE F – PROPERTY AND EQUIPMENT
Property and equipment is summarized as follows:
| (in thousands) | ||||||||
| December
31, 2024 | December
31, 2023 | |||||||
| Office, laboratory and other equipment | $ | $ | ||||||
| Equipment furnished for customer use | ||||||||
| Right of use assets - finance leases | ||||||||
| Furniture and fixtures | ||||||||
| Less: accumulated depreciation and amortization | ( | ) | ( | ) | ||||
| Property and equipment, net | $ | $ | ||||||
Accumulated
amortization of right of use (“ROU”) assets under finance leases aggregated approximately $
NOTE G – GOODWILL AND OTHER INTANGIBLES
Goodwill
of $
| (in thousands) | ||||||||
| Year ended | Year ended | |||||||
| December
31, 2024 | December
31, 2023 | |||||||
| Beginning of period | $ | $ | ||||||
| Foreign currency translation adjustment | ( | ) | ( | ) | ||||
| End of period | $ | $ | ||||||
F-22
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
The Company’s other intangible assets consist of capitalized customer-related intangibles, patent and technology costs, and software costs, as set forth in the following table:
| (in thousands) | ||||||||
| December
31, 2024 | December
31, 2023 | |||||||
| Customer-related | ||||||||
| Costs | $ | $ | ||||||
| Accumulated amortization | ( | ) | ( | ) | ||||
| Patents and Technology | ||||||||
| Costs | ||||||||
| Accumulated amortization | ( | ) | ( | ) | ||||
| Software | ||||||||
| Costs | ||||||||
| Accumulated amortization | ( | ) | ( | ) | ||||
| $ | $ | |||||||
The
Company owns, through our Chinese subsidiaries, thirty-five invention and utility patents that expire at various times through 2041,
as well as twenty-two software copyright certificates in China related to proprietary technologies in physiological data acquisition, analysis
and reporting. Costs incurred for submitting the applications to the United States Patent and Trademark Office or other foreign authorities
for these patents have been capitalized. Patent and technology costs are being amortized using the straight-line method over
Amortization
expense amounted to approximately $
| Years ending December 31, | (in thousands) | |||
| 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| $ | ||||
F-23
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
NOTE H – OTHER ASSETS
Other assets consist of the following:
| (in thousands) | ||||||||
| December 31, 2024 | December 31, 2023 | |||||||
| Deferred commission expense - noncurrent | $ | $ | ||||||
| Trade receivables - noncurrent | ||||||||
| Other, net of allowance for loss on loan receivable of $ | ||||||||
| $ | $ | |||||||
NOTE I – DEFERRED REVENUE
The changes in the Company’s deferred revenues are as follows:
| (in thousands) | ||||||||
| Year ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Deferred revenue at beginning of period | $ | $ | ||||||
| Net additions: | ||||||||
| Deferred extended service contracts | ( | ) | ||||||
| Deferred commission revenues | ||||||||
| Recognized as revenue: | ||||||||
| Deferred extended service contracts | ( | ) | ( | ) | ||||
| Deferred commission revenues | ( | ) | ( | ) | ||||
| Deferred revenue at end of period | ||||||||
| Less: current portion | ||||||||
| Long-term deferred revenue at end of period | $ | $ | ||||||
NOTE J – ACCRUED EXPENSES AND OTHER LIABILITIES
Accrued expenses and other liabilities consist of the following:
| (in thousands) | ||||||||
| December
31, 2024 | December
31, 2023 | |||||||
| Accrued compensation | $ | $ | ||||||
| Accrued expenses - other | ||||||||
| Order reduction liability | ||||||||
| Other liabilities | ||||||||
| $ | $ | |||||||
NOTE K – NOTES PAYABLE AND REVOLVING CREDIT AGREEMENT
Notes payable consists of the following:
| (in thousands) | ||||||||
| December
31, 2024 | December
31, 2023 | |||||||
| Notes payable | ||||||||
| Less: current portion | ( | ) | ( | ) | ||||
| $ | $ | |||||||
Notes
payable consists of a vehicle loan. The note is secured by the vehicle, bears interest at
F-24
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
On
December 30, 2022, the Company executed a $
NOTE L – LEASES
The
Company enters into finance leases, typically with terms of
| ● | whether expired or existing contracts contain leases under the new definition of a lease; |
| ● | lease classification for expired or existing leases; and |
| ● | whether previously capitalized initial direct costs would qualify for capitalization under Topic 842. |
Finance and operating lease liabilities consist of the following:
| (in thousands) | ||||||||
| December
31, 2024 | December
31, 2023 | |||||||
| Lease liabilities - current | ||||||||
| Finance leases | $ | $ | ||||||
| Operating leases | ||||||||
| $ | $ | |||||||
| Lease liabilities - net of current portion | ||||||||
| Finance leases | $ | $ | ||||||
| Operating leases | ||||||||
| $ | $ | |||||||
F-25
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
A reconciliation of undiscounted cash flows to finance and operating lease liabilities recognized in the consolidated balance sheet at December 31, 2024 is set forth below:
| (in thousands) | ||||||||||||
| Years ending December 31, | Finance leases | Operating leases | Total | |||||||||
| 2025 | ||||||||||||
| 2026 | ||||||||||||
| 2027 | ||||||||||||
| 2028 | ||||||||||||
| Undiscounted lease payments | ||||||||||||
| Amount representing interest | ( | ) | ( | ) | ( | ) | ||||||
| Discounted lease liabilities | ||||||||||||
Additional disclosures of lease data are set forth below:
| (in thousands) | ||||||||
| Year ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Lease costs: | ||||||||
| Finance lease costs: | ||||||||
| Amortization of right-of-use assets | $ | $ | ||||||
| Interest on lease liabilities | ||||||||
| Operating lease costs | ||||||||
| Short-term lease costs | ||||||||
| Total lease cost | $ | $ | ||||||
| Other information: | ||||||||
| Cash paid for amounts included in the measurement of lease liabilities: | ||||||||
| Operating cash flows from finance leases | $ | $ | ||||||
| Operating cash flows from operating leases | ||||||||
| Financing cash flows from finance leases | ||||||||
| $ | $ | |||||||
| December 31, 2024 | December 31, 2023 | |||||||
| Weighted-average remaining lease term - finance leases (months) | ||||||||
| Weighted-average remaining lease term - operating leases (months) | ||||||||
| Weighted-average discount rate - finance leases | % | % | ||||||
| Weighted-average discount rate - operating leases | % | % |
The Company used the rate implicit in the lease, where known, or its incremental borrowing rate as the rate used to discount the future lease payments.
NOTE M – EQUITY IN THE EECP BUSINESS
On
May 20, 2020, the Company closed on the sale of
F-26
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
The
Company uses the equity method to account for its interest in EECP Global, as it has the ability to exercise significant influence
over the entity, and reports its share of EECP Global operations in Other Income (Expense) on its consolidated statements of
operations and comprehensive income. For the years ended December 31, 2024 and 2023, the Company’s share of EECP
Global’s loss was approximately $
NOTE N – STOCKHOLDERS’ EQUITY
Chinese subsidiaries dividends and statutory reserves
The
payment of dividends by entities organized in China is subject to limitations. In particular, regulations in China currently permit
payment of dividends only out of accumulated profits as determined in accordance with People’s Republic of China
(“PRC”) accounting standards and regulations. Based on PRC accounting standards, our Chinese subsidiaries are also
required to set aside at least
NOTE O - STOCK ISSUANCE PLANS
2016 Stock Issuance Plan
On
June 15, 2016, the Board approved the 2016 Stock Plan (the “2016 Plan”) for officers, directors, and senior employees of the
Corporation or any subsidiary of the Corporation. The stock issuable under the 2016 Plan shall be shares of the Company’s authorized
but unissued or reacquired common stock. The maximum number of shares of common stock that may be issued under the 2016 Plan is
The 2016 Plan consists of a Stock Issuance Program, under which eligible persons may, at the discretion of the Board, be issued shares of common stock directly, as a bonus for services rendered or to be rendered to the Corporation or any subsidiary of the Corporation.
During
the year ended December 31, 2024, no shares of common stock were granted under the 2016 Plan and
2019 Stock Issuance Plan
In
May 2019, the Board approved the 2019 Stock Plan (the “2019 Plan”) for officers, directors, and senior employees of the Corporation
or any subsidiary of the Corporation. The stock issuable under the 2019 Plan shall be shares of the Company’s authorized but unissued
or reacquired common stock. The maximum number of shares of common stock that may be issued under the 2019 Plan is
The 2019 Plan consists of a Stock Issuance Program, under which eligible persons may, at the discretion of the Board, be issued shares of common stock directly, as a bonus for services rendered or to be rendered to the Corporation or any subsidiary of the Corporation.
F-27
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
During
the year ended December 31, 2024,
The following table summarizes non-vested restricted shares under all plans for the year ended December 31, 2024:
| Shares Available for Future Issuance | Unvested shares | Weighted Average Grant Date Fair Value | ||||||||||
| Balance at December 31, 2022 | $ | |||||||||||
| Authorized | $ | |||||||||||
| Granted | ( | ) | $ | |||||||||
| Vested | ( | ) | $ | |||||||||
| Forfeited | ( | ) | $ | |||||||||
| Expired | ( | ) | $ | |||||||||
| Balance at December 31, 2023 | $ | |||||||||||
| Authorized | $ | |||||||||||
| Granted | ( | ) | $ | |||||||||
| Vested | ( | ) | $ | |||||||||
| Forfeited | ( | ) | $ | |||||||||
| Expired | $ | |||||||||||
| Balance at December 31, 2024 | $ | |||||||||||
The Company has a total of
NOTE P - INCOME TAXES
The following is a geographical breakdown of income before the provision for income taxes:
| (in thousands) | ||||||||
| Year ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Domestic | $ | $ | ||||||
| Foreign | ( | ) | ( | ) | ||||
| Income before provision for income taxes | $ | $ | ||||||
The provision for income taxes consisted of the following:
| Year ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Current provision | ||||||||
| Federal | $ | $ | ||||||
| State | ||||||||
| Foreign | ( | ) | ||||||
| Total current provision | ||||||||
| Deferred provision | ||||||||
| Federal | ||||||||
| State | ||||||||
| Foreign | ||||||||
| Total deferred provision | ||||||||
| Total income tax provision | $ | $ | ||||||
| Effective income tax rate | % | % | ||||||
F-28
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
The
income tax expense of for the year ended December 31, 2024 was due to $
The following is a reconciliation of the effective income tax rate to the federal statutory rate:
| For the year ended | ||||||||
| December 31, 2024 | December 31, 2023 | |||||||
| % | % | |||||||
| Federal statutory rate | ||||||||
| State income taxes | ||||||||
| Change in valuation allowance relating to operations | ( | ) | ( | ) | ||||
| Foreign tax rate differential | ( | ) | ||||||
| R&D credit | ||||||||
| Nondeductible expenses | ||||||||
| Other | ( | ) | ||||||
The effective tax rate increased mainly due to higher state income taxes in 2024.
As of December 31, 2024, the
recorded deferred tax assets were , reflecting a decrease of $
The components of our deferred tax assets and liabilities are summarized as follows:
| (in thousands) | ||||||||
| December 31, 2024 | December 31, 2023 | |||||||
| Deferred Tax Assets: | ||||||||
| Net operating loss carryforwards | $ | $ | ||||||
| Amortization | ||||||||
| Stock-based compensation | ||||||||
| Allowance for doubtful accounts | ||||||||
| Reserve for slow moving inventory | ||||||||
| Tax credits | ||||||||
| Expense accruals | ||||||||
| Capitalized R&D | ||||||||
| Deferred revenue | ||||||||
| Total gross deferred taxes | ||||||||
| Valuation allowance | ( | ) | ( | ) | ||||
| Net deferred tax assets | ||||||||
| Deferred Tax Liabilities: | ||||||||
| Deferred commissions | ( | ) | ( | ) | ||||
| Goodwill | ( | ) | ( | ) | ||||
| Depreciation | ( | ) | ( | ) | ||||
| Total deferred tax liabilities | ( | ) | ( | ) | ||||
| Total deferred tax assets | ||||||||
| Recorded as: | ||||||||
| Non-current deferred tax assets | ||||||||
| Non-current deferred tax liabilities | ||||||||
| Total deferred tax assets | $ | $ | ||||||
F-29
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
The activity in the valuation allowance is set forth below:
| (in thousands) | ||||||||
| 2024 | 2023 | |||||||
| Valuation allowance, January 1, | $ | $ | ||||||
| Change in valuation allowance | ( | ) | ( | ) | ||||
| Valuation allowance, December 31, | $ | $ | ||||||
At
December 31, 2024, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $
Under current tax law, the utilization of tax attributes will be restricted if an ownership change, as defined, were to occur. Section 382 of the Internal Revenue Code provides, in general, that if an “ownership change” occurs with respect to a corporation with net operating and other loss carryforwards, such carryforwards will be available to offset taxable income in each taxable year after the ownership change only up to the “Section 382 Limitation” for each year (generally, the product of the fair market value of the corporation’s stock at the time of the ownership change, with certain adjustments, and a specified long-term tax-exempt bond rate at such time). The Company’s ability to use its loss carryforwards will be limited in the event of an ownership change.
NOTE Q - COMMITMENTS AND CONTINGENCIES
Sales representation agreement
In October 2021, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010 and previously extended in 2012, 2015 and 2017. The amendment extended the term of the original agreement, which began on July 1, 2010, through December 31, 2026, subject to early termination by GEHC without cause with certain conditions. Under the agreement, VasoHealthcare is the exclusive representative for the sale of select GEHC diagnostic imaging and ultrasound products to specific market accounts in the 48 contiguous states of the United States and the District of Columbia. The circumstances under which early termination of the agreement may occur with cause include: not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and not meeting various legal and GEHC policy requirements. The Company met all the contractual conditions in 2024.
Employment Agreements
On
May 10, 2019, the Company modified its Employment Agreement with its President and Chief Executive Officer, Dr. Jun Ma, to provide
for a five-year term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond May 31, 2026.
The Employment Agreement provides for annual compensation of $
F-30
Vaso Corporation and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Years Ended December 31, 2024 and 2023
On
December 31, 2022, the Company executed an Employment Agreement with the President of its VasoHealthcare subsidiary, Ms. Jane Moen, to
provide for a twenty-seven month initial term with extensions, unless earlier terminated by the Company, but in no event can it extend
beyond December 31, 2026 or the earlier termination of the GEHC Agreement. The Employment Agreement provides for annual base compensation
of $
Licensing and Support Service Agreement
In
November 2024, NetWolves extended the licensing and support service agreement of its billing system for an additional four years, to
expire December 2028. The agreement provides for monthly recurring charges based on a percentage of billed revenues using these
services, which charges aggregated approximately $
Litigation
The Company is currently, and has been in the past, a party to various routine legal proceedings, primarily employee related matters, incident to the ordinary course of business. The Company believes that the outcome of all such pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company.
Foreign operations
During the years ended December 31, 2024 and 2023, the Company had and continues to have operations in China. Operating transactions in China are denominated in the Chinese currency called RMB or CNY, which is not freely convertible into foreign currencies. Operating internationally involves additional risks relating to such things as currency exchange rates, different legal and regulatory environments, political, economic risks relating to the stability or predictability of foreign governments, differences in the manner in which different cultures do business, difficulties in staffing and managing foreign operations, differences in financial reporting, operating difficulties, and other factors.
Commercial law is still developing in China and there are limited legal precedents to follow in commercial transactions. There are many tax jurisdictions, each of which may have changing tax laws. Applicable taxes include value added taxes (“VAT”), Enterprise Income Tax, and social (payroll) taxes. Foreign tax regulations are often unclear. Tax declarations (reports) are subject to review and taxing authorities may impose fines, penalties and interest. These facts create risks in China.
NOTE R - 401(k) PLANS
The
Company maintains a defined contribution plan to provide retirement benefits for its employees - the Vaso Corporation 401(k) Plan adopted
in April 1997. As allowed under Section 401(k) of the Internal Revenue Code, the plan provides tax-deferred salary deductions for eligible
employees. Employees are eligible to participate in the next quarter enrollment period after employment and participants may make voluntary
contributions to the plan up to
F-31
Exhibit 10(g)
[*] INDICATES REDACTED TEXT
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this “Agreement”), made and entered into as of October 1, 2022, by and between VASO CORPORATION, a Delaware corporation, with its principal office located at 137 Commercial Street, Suite 200, Plainview, NY 11803 (together with its successors and assigns permitted under this Agreement, “VASO”) and Jane Moen, residing at 720 N. Larrabee Street, No. 1412, Chicago, IL 60654 (“Employee”).
WITNESSETH:
WHEREAS, VASO has employed Employee as President of Vaso Diagnostics, Inc. d/b/a VasoHealthcare Sales Professionals (“VasoHealthcare”), a wholly owned subsidiary of VASO; and
WHEREAS, VASO wishes to assure itself of the services of Employee for the period hereinafter provided, and Employee is willing to continue to be employed by VASO for said period, upon the terms and conditions provided in this Agreement;
NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein and for other good and valuable consideration, the receipt of which is mutually acknowledged, VASO and Employee (individually a “Party” and together the “Parties”) agree as follows:
| 1. | DEFINITIONS |
| (a) | “Affiliate” shall mean any person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such person. For the purpose of this definition, “control” when used with respect to any person means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such person whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing. |
| (b) | “Beneficiary” shall mean the person or persons named by Employee pursuant to Section 14 below or, in the event that no such person is named who survives Employee, her estate. |
| (c) | “Board” shall mean the Board of Directors of VASO. |
| (d) | “Cause” shall mean: |
| (i) | Employee’s conviction of, or pleading guilty to, a felony or nolo contender to a charge of any felony or of any lesser crime involving fraud or moral turpitude, excluding DWI (or other similar offense); | |
| (ii) | willful refusal of Employee to perform her material duties under this Agreement, resulting in material economic harm to VASO; or | |
| (iii) | a material breach by Employee of the provisions of Sections 11 or 12 of this Agreement. |
Page 1 of 10
| (e) | “Change in Control” shall mean the occurrence of any of the following events during the Employment Term: |
| (i) | a majority of the members of the Board is replaced during any 30-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; | |
| (ii) | the consummation of a reorganization, merger, consolidation or similar form of transaction involving VASO (“Business Combination”); excluding, however, such a Business Combination pursuant to which all or substantially all of the individuals and entities who were the beneficial owners of the outstanding VASO voting securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than fifty percent (50%) of the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors of the corporation resulting from such Business Combination in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the outstanding VASO voting securities; or | |
| (iii) | a complete liquidation or dissolution of VASO or VasoHealthcare, or sale or other disposition of all or substantially all of the assets of VASO or VasoHealthcare, other than to any Subsidiary. |
Notwithstanding the foregoing, a Change in Control shall not include any event, circumstance or transaction that results from any action of any person, entity or group which includes or is wholly or partly controlled by one or more executive officers of VASO and in which Employee participates directly or actively (other than renegotiation of her employment arrangements or in her capacity as an employee or director of VASO or any successor entity thereto or to the business of VASO).
| (f) | “Committee” shall mean the Compensation Committee of the Board. |
| (g) | “Disability” shall mean the illness or other mental or physical disability of Employee, as determined by a physician acceptable to VASO and Employee, resulting in her failure during the Employment Term to perform substantially her applicable material duties under this Agreement for a period of three (3) consecutive months. |
| (h) | “Employment Term” shall mean the period specified in Section 2(b) below. |
| (i) | “Fiscal Year” shall mean the 12-month period beginning on or about January 1 and ending on or about the next subsequent December 31, or such other 12-month period as may constitute VASO’s fiscal year at any time hereafter. |
| (j) | “Good Reason” shall mean, at any time during the Employment Term, in each case without Employee’s prior written consent, |
| (i) | reduction in Employee’s then current Salary; or | |
| (ii) | VASO’s failure to pay Employee any amounts otherwise vested and due her under Sections 3 and 4 hereof which breach is not cured within thirty (30) business days after written notification to VASO of such breach; or | |
| (iii) | a failure of VASO to have any successor in the event of Change in Control to assume in writing the obligations under this Agreement. |
| (k) | “Representation Agreement” shall mean the sales representation agreement between VasoHealthcare and GE Healthcare currently in effect which expires, subject to earlier termination, on December 31, 2026 (the “Representation Agreement”). |
Page 2 of 10
| (l) | “Salary” shall mean the annual salary provided for in Section 3 below, as adjusted from time to time. |
| (m) | “Subsidiary” shall mean any corporation of which VASO owns, directly or indirectly, more than fifty percent (50%) of its voting stock. |
| 2. | EMPLOYMENT TERM, POSITIONS AND DUTIES |
| (a) | Employment of Employee. VASO hereby agrees to employ Employee, and Employee hereby accepts employment with VASO, in the positions and with the duties and responsibilities set forth below and upon such other terms and conditions as are hereinafter stated. Employee shall render services to VASO and shall do such traveling on behalf of VASO as shall be reasonably required in the course of the performance of her duties hereunder. |
| (b) | Employment Term. The Employment Term shall commence as of October 1, 2022 (the “Commencement Date”) and shall terminate on December 31, 2024 provided that the Employment Term shall extend for additional one-year periods annually each December 31 commencing December 31, 2022, unless this Agreement is terminated pursuant to the provisions of Section 10 below. In no event, however, shall the Employment Term extend beyond December 31, 2026 or the earlier termination of the Representation Agreement. |
| (c) | Titles and Duties. Until the date of termination of her employment hereunder, Employee shall be employed as President of VasoHealthcare, reporting to the President and CEO of VASO. In her capacity as President of VasoHealthcare, Employee shall have the customary powers, responsibilities and authorities of presidents of corporations of the size, type and nature of VasoHealthcare. |
| (d) | Time and Effort. |
| (i) | Employee agrees to devote her best efforts and abilities, and her full time and attention, to the affairs of VasoHealthcare in order to carry out her duties and responsibilities under this Agreement. | |
| (ii) | Notwithstanding the foregoing, nothing shall preclude Employee from (i) serving on the boards of a reasonable number of trade associations, charitable organizations and/or businesses not in competition with VASO, (ii) engaging in charitable activities and community affairs, and (iii) managing her personal investments and affairs; provided, however, that, such activities do not interfere with the proper performance of her duties and responsibilities specified in Section 2 (c) above. |
| 3. | SALARY |
| (a) | Base Salary. Employee shall receive from VASO a Salary, payable in accordance with the regular payroll practices of VASO, at the annual rate of $350,000. |
| (b) | Salary Increase. During the Employment Term, Employee shall be eligible for periodic annual increases in Salary commencing January 1, 2024 in the sole discretion of the Committee. |
Page 3 of 10
| 4. | BONUSES |
| (a) | Annual Employment Bonus. For the Fiscal Year ending on December 31, 2022 and for each Fiscal Year thereafter during the Employment Term, Employee shall receive an annual bonus of $100,000 (prorated for fiscal year 2022), paid within ninety (90) days after the end of each Fiscal Year. |
| (b) | Annual Performance Bonus. For the Fiscal Year ending on December 31, 2022 and for each Fiscal Year thereafter during the Employment Term, Employee shall be eligible to receive an annual performance bonus of up to $200,000, paid within nine (90) days after the end of each Fiscal Year, in accordance with each of the following performance criteria: |
| (i) | $50,000 if VasoHealthcare reaches [*] of its overall annual operating plan (“OP”), [*]; | |
| (ii) | $50,000 if VasoHealthcare reaches [*] of its overall annual OP and if VasoHealthcare’s annual selling, general and administrative (“SG&A”) expenses as recorded and reported in VASO’s annual report does not exceed the budgeted amount for the Fiscal Year; | |
| (iii) | $50,000 if VasoHealthcare earns a [*] commission rate of [*]; | |
| (iv) | $50,000 if VasoHealthcare achieves annual target of equipment delivery volume per VasoHealthcare budget set in the beginning of each Fiscal Year. |
| 5. | LONG-TERM INCENTIVE |
During the Employment Term, Employee shall be eligible for an award under any long-term incentive compensation plan established by VASO for the benefit of Employee or, in the absence thereof, under any such plan that may be established for the benefit of members of the senior management of VASO.
| 6. | EQUITY GRANTS |
As a condition to her employment, Employee shall be eligible to receive further grants of options to purchase shares of VASO stock and awards of shares of VASO stock, either or both as determined by the Committee, under and in accordance with the terms of applicable plans of VASO and related option and award agreements.
| 7. | EXPENSE REIMBURSEMENT; CERTAIN OTHER COSTS |
During the Employment Term, Employee shall be entitled to prompt reimbursement by VASO for all reasonable out-of-pocket expenses incurred by her in performing services under this Agreement.
| 8. | PERQUISITES |
During the Employment Term, VASO shall provide Employee with secretarial and other assistance, as well as vehicle allowance or use of an automobile and reimbursement of related expenses.
| 9. | EMPLOYEE BENEFIT PLANS |
| (a) | General. During the Employment Term, Employee shall be entitled to participate in employee benefit plans and programs made available to VASO’s senior executives or to its employees generally, as such plans or programs may be in effect from time to time, including, without limitation, pension and other retirement plans, profit-sharing plans, savings and similar plans, group life insurance, accidental death and dismemberment insurance, travel accident insurance, hospitalization insurance, surgical insurance, major and excess major medical insurance, dental insurance, short-term and long-term disability insurance, sick leave (including salary continuation arrangements), holidays, vacation (not less than four weeks in any calendar year) and any other employee benefit plans or programs that may be sponsored by VASO from time to time, including plans that supplement the above-listed types of plans, whether funded or unfunded. |
Page 4 of 10
| (b) | Medical Care Reimbursement and Insurance. During the Employment Term VASO shall provide Employee with life insurance, hospitalization insurance, surgical insurance, major and excess major medical insurance and dental insurance in accordance with the plans, policies, programs and practices of VASO made available generally to other senior executive officers of VASO. |
| 10. | TERMINATION OF EMPLOYMENT |
| (a) | Voluntary Termination and Termination by Mutual Agreement. The Parties may terminate this Agreement by mutual written agreement at any time, and if they do so, Employee’s entitlements shall be as the Parties mutually agree. |
| (b) | General. Notwithstanding anything to the contrary herein, in the event of termination of Employee’s employment under this Agreement, she or her Beneficiary, as the case may be, shall be entitled to receive (in addition to payments and benefits under, and except as specifically provided in, Subsections (c) through (g) below, as applicable): |
| (i) | her Salary through the date of termination; | |
| (ii) | any annual bonus awarded but not yet paid to her; | |
| (iii) | any other compensation or benefits, including without limitation long-term incentive compensation described in Section 5 above, benefits under equity grants and awards described in Section 6 above and employee benefits under plans described in Section 9 above, that have vested through the date of termination or to which she may then be entitled in accordance with the applicable terms and conditions of each grant, award or plan; and | |
| (iv) | reimbursement in accordance with Sections 9(a) and (b) above of any business and medical expenses incurred by Employee, as applicable, through the date of termination but not yet paid to her. |
| (c) | Termination due to Death. In the event that Employee’s employment is terminated due to her death, her Beneficiary shall be entitled, in addition to the compensation and benefits specified in Section 10(b), to six (6) months’ Salary payable in six (6) equal monthly installments and commencing on the first payroll period following her death. |
| (d) | Termination due to Disability. In the event of Employee’s Disability, VASO may terminate Employee’s employment. If Employee’s employment is terminated due to Disability, she shall be entitled, in addition to the compensation and benefits specified in Section 10(b), to severance equal to six (6) months’ Salary payable in six (6) equal monthly installments commencing on the first payroll period following such termination. |
| (e) | Termination by VASO for Cause. In the event that Employee’s employment is terminated for Cause, she shall be entitled only to the compensation and benefits specified in Section 10(b). |
Page 5 of 10
| (f) | Termination by VASO Without Cause or by Employee for Good Reason. VASO may terminate Employee’s employment hereunder without Cause and Employee may terminate her employment hereunder for Good Reason, in each case on ninety (90) days prior written notice. If, during the Employment Term, VASO terminates Employee’s employment without Cause or Employee terminates her employment for Good Reason, in either such case, she shall be entitled to receive, subject to the execution and non-revocation of a release satisfactory to Vaso as to Employee’s continued compliance with the restrictive covenants contained in Sections 11 and 12, and in addition to the compensation and benefits specified in Section 10(b): |
| (i) | payment of $20,000 per month for twenty-four (24) months commencing as soon as practicable following such termination; | |
| (ii) | bonuses, prorated for the duration of employment in the year of termination, which would have otherwise been paid for the year of termination had Employee’s employment not been terminated, to be paid at such time as such bonus would otherwise have been paid; and | |
| (ii) | coverage under COBRA for twelve (12) months following her effective date of termination if Employee (or her beneficiaries) elect continued medical coverage under COBRA. |
| (g) | Vesting of Equity Upon Certain Terminations. If, during the Employment Term, VASO terminates Employee’s employment without Cause or Employee terminates her employment for Good Reason, in either such case, all unvested options and shares shall vest in full as of the effective date of termination. |
| 11. | CONFIDENTIAL INFORMATION |
| (a) | General. |
| (i) | Employee understands and hereby acknowledges that, as a result of her employment with VASO, she will necessarily become informed of and have access to certain valuable and confidential information of VASO and any of its Subsidiaries, joint ventures and affiliates, including, without limitation, inventions, trade secrets, technical information, product and customer information, computer software and programs, know-how and plans (“Confidential Information”), and that any such Confidential Information, even though it may be developed or otherwise acquired by Employee, is the exclusive property of VASO to be held by her in trust solely for VASO’s benefit. | |
| (ii) | Accordingly, Employee hereby agrees that, during the Employment Term and subsequent thereto, she shall not, and shall not cause others to, use, reveal, report, publish, transfer or otherwise disclose to any person, corporation or other entity any Confidential Information without prior written consent of the Board, except to responsible officers and employees of VASO. Notwithstanding, the foregoing, the prohibitions of this Clause 11(a)(ii) shall not apply to any Confidential Information that becomes of general public knowledge other than from VASO or Employee. |
| (b) | Return of Documents. Upon termination of her Employment Term with VASO for any reason, Employee shall promptly deliver to VASO all plans, drawings, manuals, letters, notes, notebooks, reports, computer programs and copies thereof and all other materials, including without limitation those of a secret or confidential nature, relating to VASO’s business that are then in her possession or control. |
Page 6 of 10
| (c) | Remedies and Sanctions. In the event that Employee is found to be in violation of Section 11(a) or (b) above, VASO shall be entitled to relief as provided in Section 13 below. |
| 12. | NON-COMPETITION/NON-SOLICITATION |
| (a) | Prohibitions. During the Employment Term and for a period of twenty-four (24) months thereafter, Employee shall not, without prior written authorization of the Board, directly or indirectly, through any other individual or entity: |
| (i) | become an officer or employee of, or render any service to, any direct or indirect competitor of VASO or any of its Subsidiaries or to any individual or entity engaged in the manufacture, distribution, marketing or sale of medical imaging products. | |
| (ii) | solicit or induce any customer of VASO to cease purchasing goods or services from VASO or to become a customer of any competitor of VASO; or | |
| (iii) | solicit or induce any employee of VASO to become employed by any competitor of VASO. |
| (b) | Remedies and Sanctions. In the event that Employee is found to be in violation of Section 12(a) above, VASO shall be entitled to relief as provided in Section 13 below. |
| (c) | Exceptions. Notwithstanding anything to the contrary in Section 12(a) above, its provisions shall not be construed as preventing Employee from investing her assets in any business that is not a direct competitor of VASO. |
| 13. | REMEDIES/SANCTIONS |
Employee acknowledges that the services she is to render under this Agreement are of a unique and special nature, the loss of which cannot reasonably or adequately be compensated for in monetary damages, and that irreparable injury and damage may result to VASO in the event of any breach of this Agreement or default by Employee. Because of the unique nature of the Confidential Information and the importance of the prohibitions against competition and solicitation, Employee further acknowledges and agrees that VASO will suffer irreparable harm if she fails to comply with her obligations under Section 13(a) or (b) above or Section 14(a) above and that monetary damages would be inadequate to compensate VASO for any such breach. Accordingly, Employee agrees that, in addition to any other remedies available to either Party at law, in equity or otherwise, VASO will be entitled to seek injunctive relief or specific performance to enforce the terms, or prevent or remedy the violation, of any provisions of this Agreement.
| 14. | BENEFICIARIES/REFERENCES |
Employee shall be entitled to select (and change, to the extent permitted under any applicable law) a beneficiary or beneficiaries to receive any compensation or benefit payable under this Agreement following her death by giving VASO written notice thereof. In the event of Employee’s death, or of a judicial determination of her incompetence, reference in this Agreement to Employee shall be deemed to refer, as appropriate, to her beneficiary, estate or other legal representative.
Page 7 of 10
| 15. | WITHHOLDING TAXES |
All payments to Employee or her Beneficiary under this Agreement shall be subject to withholding on account of federal, state and local taxes as required by law.
| 16. | INDEMNIFICATION AND LIABILITY INSURANCE |
Nothing herein is intended to limit VASO’s indemnification of Employee, and VASO shall indemnify her to the fullest extent permitted by applicable law consistent with VASO’s Certificate of Incorporation and By-Laws as in effect at the beginning of the Employment Term, with respect to any action or failure to act on her part while she is an officer, director or employee of VASO or any Subsidiary. VASO shall cause Employee to be covered at all times by directors’ and officers’ liability insurance.
| 17. | EFFECT OF AGREEMENT ON OTHER BENEFITS |
The existence of this Agreement shall not prohibit or restrict Employee’s entitlement to participate fully in compensation, employee benefit and other plans of VASO in which senior executives are eligible to participate.
| 18. | ASSIGNABILITY; BINDING NATURE |
This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors, heirs (in the case of Employee) and assigns. No rights or obligations of VASO under this Agreement may be assigned or transferred by VASO except pursuant to (a) a merger or consolidation in which VASO is not the continuing entity or (b) sale or liquidation of all or substantially all of the assets of VASO, provided that the surviving entity or assignee or transferee is the successor to all or substantially all of the assets of VASO and such surviving entity or assignee or transferee assumes the liabilities, obligations and duties of VASO under this Agreement, either contractually or as a matter of law.
VASO further agrees that, in the event of a sale of assets or liquidation as described in the preceding sentence, it shall use reasonable commercial efforts to have such assignee or transferee expressly agree to assume the liabilities, obligations and duties of VASO hereunder. No rights or obligations of Employee under this Agreement may be assigned or transferred by her.
| 19. | REPRESENTATIONS |
The Parties respectively represent and warrant that each is fully authorized and empowered to enter into this Agreement and that the performance of its or her obligations, as the case may be, under this Agreement will not violate any agreement between such Party and any other person, firm or organization. VASO represents and warrants that this Agreement has been duly authorized by all necessary corporate action and is valid, binding and enforceable in accordance with its terms.
| 20. | ENTIRE AGREEMENT |
Except to the extent otherwise provided herein, this Agreement contains the entire understanding and agreement between the Parties concerning the subject matter hereof and supersedes any prior agreements, whether written or oral, between the Parties concerning the subject matter hereof. Payments and benefits provided under this Agreement are in lieu of any payments or other benefits under any severance program or policy of VASO to which Employee would otherwise be entitled.
Page 8 of 10
| 21. | AMENDMENT OR WAIVER |
No provision in this Agreement may be amended unless such amendment is agreed to in writing and signed by both Employee and an authorized officer of VASO. No waiver by either Party of any breach by the other Party of any condition or provision contained in this Agreement to be performed by such other Party shall be deemed a waiver of a similar or dissimilar condition or provision at the same or any prior or subsequent time. Any waiver must be in writing and signed by the Party to be charged with the waiver. No delay by either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof.
| 22. | SEVERABILITY |
In the event that any provision or portion of this Agreement shall be determined to be invalid or unenforceable for any reason, in whole or in part, the remaining provisions of this Agreement shall be unaffected thereby and shall remain in full force and effect to the fullest extent permitted by law.
| 23. | SURVIVAL |
The respective rights and obligations of the Parties under this Agreement shall survive any termination of Employee’s employment with VASO.
| 24. | GOVERNING LAW/JURISDICTION |
This Agreement shall be governed by and construed and interpreted in accordance with the laws of New York, without reference to principles of conflict of laws. Any action or proceeding brought to enforce any of the provisions of this Agreement and/or to seek other relief for breach thereof must be instituted in a federal or state court situated in the State of New York, Nassau County, to the jurisdiction of which courts the Parties irrevocably and unconditionally submit.
| 25. | NOTICES |
Any notice given to either Party shall be in writing and shall be deemed to have been given when delivered either personally, by overnight delivery service (such as Federal Express), or sent by electronic mail or by certified or registered mail postage prepaid, return receipt requested, duly addressed to the Party concerned at the address indicated below or to such changed address as the Party may subsequently give notice of.
| If to VASO or the Board: | Vaso Corporation | |
| 137 Commercial Street, Suite 200 | ||
| Plainview, NY 11803 | ||
| Attn: Jun Ma, President and CEO | ||
| Email: jma@vasocorporation.com | ||
| With a copy to: | Ortoli Rosenstadt, LLP | |
| 366 Madison Ave, 3rd Fl. | ||
| New York, New York 10017 | ||
| Attn: David Lieberman | ||
| Email: dlieberman@blbllp.com | ||
| If to Employee: | Jane Moen | |
| 720 N. Larrabee Street, No. 1412 | ||
| Chicago, IL 60654 | ||
| Email: jmoen@vasohealthcare.com | ||
| 26. | HEADINGS |
The headings of the sections contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement.
| 27. | COUNTERPARTS |
This Agreement may be executed in counterparts, each of which when so executed and delivered shall be an original, but all such counterparts together shall constitute one and the same instrument.
Page 9 of 10
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of December 31, 2022.
| Vaso Corporation | ||
| By: | /s/ Jun Ma | |
| Jun Ma | ||
| President & CEO | ||
| EMPLOYEE | ||
| By: | /s/ Jane Moen | |
| Jane Moen | ||
Page 10 of 10
Exhibit 19
INSIDER TRADING
Federal and state securities laws prohibit the purchase or sale of securities by persons who are aware of material nonpublic information about a company, as well as the disclosure of material, nonpublic information about a company to others who then trade in the company’s securities. These transactions are commonly known as “insider trading” and “tipping”, respectively.
Employees, officers and directors of the Company (“Covered Persons”) shall not, directly or indirectly through their families or other third parties, buy or sell the Company’s securities while in possession of material non-public information. To avoid even the appearance of insider trading, Covered Persons shall not trade in options in the company’s stock and shall avoid speculating in the Company’s stock. All Covered Persons shall follow the guidelines on securities trading issued by the Company.
Material information is any information that could reasonably be expected to affect the value of a stock. If a Covered Person is considering buying or selling a stock because of inside information they may possess, they should assume that such information is material. It is also important for the Covered Person to keep in mind that if any trade they make becomes the subject of an investigation by the government, the trade will be viewed after-the-fact with the benefit of hindsight. Consequently, Covered Persons should always carefully consider how their trades would look from this perspective.
The kinds of events or information that are often considered material include, among other things:
| o | strategic plans, forecast/volume information | o | significant capital investment plans | |
| o | a significant cybersecurity incident that has not yet been made public | o | financial performance, especially quarterly and year-end earnings | |
| o | new major contracts, orders, suppliers, customers, or finance sources, or the loss thereof | o | significant changes in financial performance outlook or liquidity of the Company | |
| o | negotiations concerning mergers and acquisitions or dispositions | o | major new contracts (or the loss of a major contract) | |
| o | actual or threatened major litigation, or the resolution of such litigation | o | a change in control or a significant change in management | |
| o | impending securities splits, securities dividends or changes in dividends to be paid | o | other favorable or unfavorable business or financial developments, projections or prospects | |
| o | significant changes or developments in regulatory status or impending regulatory action, including approvals or denials of requests for regulatory approval by government agencies |
1
Information should be considered “non-public” until it has been disseminated by the company that it concerns in a manner designed to reach investors generally and investors have been given the opportunity to absorb the information – generally at least two full business days after the date the information was disclosed. The fact that information has been disclosed to a few members of the public does not make such information public for insider trading purposes. In general, officers and directors are presumed to be in possession of material non-public information during each scheduled quarterly, and any specially designated, Blackout period, as described below.
The Company has established permitted trading windows in an attempt to assist officers and directors in avoiding trading in the Company’s securities when they are likely to have material, non-public information about the Company:
| ● | Quarterly Trading Windows. Provided that no other restrictions on trading in Company securities apply, officers and directors may trade in Company securities only during the period beginning two (2) full trading days following the Company’s widespread public release of quarterly or year-end earnings and ending 30 days before the last day of the following fiscal quarter, except as otherwise determined by the Board. |
| ● | Blackout Periods. From time to time the Company may determine that officers and directors or other employees possess material, non-public information and, in response, establish periods during which no officer or director or other employee, as applicable, may trade in the Company’s securities (a “Blackout”). No Covered Person, whether or not subject to a special Blackout period, may disclose to any outside third party that a special Blackout period has been designated. |
| ● | Officers and directors should pre-clear all trades with the Company’s Compliance Officer (defined below). |
Insiders found liable for insider trading may be subject to both civil and criminal penalties. Companies that knowingly and recklessly fail to prevent insider trading by their employees are subject to a civil penalty and a criminal fine. Employees, officers or directors who are found in violation of this Policy will be subject to disciplinary action as outlined in the Employee Handbook, including termination of employment. The Company has appointed the Chief Financial Officer as the compliance officer for this Policy (the “Compliance Officer”). If you have questions about the policy or whether you may trade in securities of the Company at any time without violating the policy, please contact the Compliance officer.
2
Exhibit 31
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Jun Ma, certify that:
| 1. | I have reviewed this report on Form 10-K of Vaso Corporation and subsidiaries (the “registrant”); |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| /s/ Jun Ma. | |
| Jun Ma | |
| President and Chief Executive Officer | |
| Dated: March 31, 2025 |
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Jonathan Newton, certify that:
| 1. | I have reviewed this report on Form 10-K of Vaso Corporation and subsidiaries (the “registrant”); |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| /s/ Jonathan Newton | |
| Jonathan Newton | |
| Chief Financial Officer | |
| Dated: March 31, 2025 |
Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Jun Ma, President and Chief Executive Officer of Vaso Corporation (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:
| (1) | the Annual Report on Form 10-K of the Company for the year ended December 31, 2024 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ Jun Ma. | |
| Jun Ma | |
| President and Chief Executive Officer | |
| Dated: March 31, 2025 |
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Jonathan Newton, Chief Financial Officer of Vaso Corporation (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:
| (1) | the Annual Report on Form 10-K of the Company for the year ended December 31, 2024 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ Jonathan Newton | |
| Jonathan Newton | |
| Chief Financial Officer | |
| Dated: March 31, 2025 |